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ABSTRACT  
   
In the United States, Escherichia coli O157:H7 (E. coli O157:H7) is the most 
frequent cause of hemolytic uremic syndrome (HUS) and it is also the primary 
cause of acute renal failure in children. The most common route of the infection is 
ingestion of contaminated meat or dairy product originating from cattle or 
vegetables contaminated with bovine manure. Since cattle are the main reservoir 
for human infection with E. coli O157:H7, the reduction of intestinal colonization 
by these bacteria in cattle is the best approach to prevent human infections. 
Intimin is an outer membrane protein of E. coli O157:H7 that plays an important 
role in adhesion of the bacteria to the host cell. Hence, I proposed to express 
intimin protein in tomato plants to use it as a vaccine candidate to reduce or 
prevent intestinal colonization of cattle with E. coli O157:H7. I expressed His-
tagged intimin protein in tomato plants and tested the purified plant-derived 
intimin as a vaccine candidate in animal trials. I demonstrated that mice 
immunized intranasally with purified tomato-derived intimin produced intimin-
specific serum IgG1and IgG2a, as well as mucosal IgA. I further demonstrated 
that mice immunized with intimin significantly reduced time of the E. coli 
O157:H7 shedding in their feces after the challenge with these bacteria, as 
compared to unimmunized mice.  
Shiga toxin is the major virulence factor that contributes to HUS. Since Shiga 
toxin B subunit has an important role in the attachment of the toxin to its receptor, 
I fused intimin to Shiga toxin B subunit to create multivalent subunit vaccine and 
tested the effects upon immunization of mice with the B subunit when combined 
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with intimin. His-tagged intimin, Shiga toxin B subunit, and Shiga toxin-intimin 
fusion proteins were expressed in E. coli and purified. I demonstrated that this 
multivalent fusion protein vaccine candidate elicited intimin- and Shiga toxin B-
specific IgG1, IgG2a, and IgA antibodies in mice. I also showed a reduction in the 
duration of the bacterial shedding after the challenge compared to the control 
sham-immunized groups.  
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Chapter 1 
INTRODUCTION 
1.1 Pathogenic Escherichia coli 
The bacterial species Escherichia coli was first described in 1885 by a German 
pediatrician and bacteriologist Theodore Escherich. E. coli is a gram negative, 
facultative anaerobe and characteristically colonizes the gastrointestinal tract of 
warm blooded animals and humans within a few hours after the birth (Nataro and 
Kaper 1998). E. coli lives in a mutualistic relationship with humans, where it 
benefits from the warmth, shelter, and nutrients provided by the colon, and in 
return make vitamin K. It also serves as a competitive inhibitor of pathogenic 
bacteria.  E. coli live in a healthy host without causing any disease, but sometimes 
even non-pathogenic E. coli strains can cause diseases in an immunosuppressed 
host or in a host having disrupted gastrointestinal barriers (Kaper, J.P. et al. 2004).  
Although E. coli is a probiotic commensal bacterium, some strains evolved to 
have virulence factors adapted to different environments allowing them to cause a 
wide variety of diseases. The combination of different virulence factors creates 
different pathotypes of E. coli. According to general clinical syndromes, 
pathogenic E. coli can be responsible for sepsis/meningitis, urinary tract 
infections, and enteric/diarrheal disease.  Diarrheagenic E. coli can further be 
categorized into six pathotypes: enterotoxigenic E. coli (ETEC), 
enteroaggravative E. coli (EAEC), diffusely adherent E. coli (DAEC), 
enteropathogenic E. coli (EPEC), and enterohaemorrhagic E. coli (EHEC).  
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Furthermore, E. coli serotypes are identified based on combination of the O 
(lipopolysaccharide, LPS) and H (flagellar) antigens, such as in E. coli O157:H7.   
In 1983 Karmali et al.(Karmali, Petric et al. 1983) described a cytotoxin produced 
by E. coli strains that is toxic for African green monkey kidney cells (Vero cells) 
and causes sporadic cases of hemolytic uremic syndrome. Subsequently, Riley et 
al. (Riley, Remis et al. 1983) identified E. coli O157:H7 as a cause of bloody 
diarrhea after the two main outbreaks of gastrointestinal illness in the United 
States. Riley et al. (1983) described the illness as characterized by severe 
abdominal cramps, bloody diarrhea and little or no fever. O’Brien et al. (O'Brien, 
Lively et al. 1983) documented that E. coli O157:H7 produces a toxin very 
similar to the toxin from Shigella dysenteriae: Shiga toxin. Since then, different 
studies revealed EHEC as a cause of hemolytic uremic syndrome (HUS) and non-
bloody/bloody diarrhea (Karch, Tarr et al. 2005) in the United States and all 
around the world.  
 
1.2. EHEC O157:H7 Infection and Epidemiology: 
Individuals infected by EHEC O157:H7 can possibly experience an illness 
ranging from mild or bloody diarrhea to HUS. HUS is characterized by 
microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure 
(Scheiring, Andreoli et al. 2008). HUS can also further be divided into diarrhea 
(D+) and non-diarrhea associated (D-) disease. D+ HUS is generally associated 
with E. coli O157:H7 infection. Indeed, EHEC O157:H7-mediated HUS is the 
primary cause of acute renal failure in children in the United States and Canada.  
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In the United States 73,480 infections, 2168 hospitalizations, and 61 deaths occur 
per year (Mead, Slutsker et al. 1999; Yoon and Hovde 2008) with an estimated 
annual disease cost of $0.5-$3.3 billion (Frenzen, Drake et al. 2005).   
Human infection with E. coli O157:H7 has been reported in more than 30 
countries.  Epidemiological studies have shown that EHEC O157:H7 can be 
found in domestic animals, especially in cattle, regardless of geographical regions 
(Beutin 2006). Since a very wide spread outbreak of EHEC O157:H7 infections in 
humans in the United States in 1982, which was associated with ground beef 
consumption, the bovine reservoir has been confirmed as a source of these 
infections (Armstrong, Hollingsworth et al. 1996). Cattle infected with EHEC 
O157:H7 can remain asymptomatic although they still shed the bacteria into the 
environment through their feces. Environmental contamination with EHEC 
O157:H7 caused by infected cattle has been increasingly reported in the last 10 
years (Fremaux, Prigent-Combaret et al. 2008). Infected cattle can contaminate 
drinking water sources, soil, and vegetables. Epidemiological studies also 
confirmed that a variety of bovine products such as ground beef, roast beef, and 
raw dairy products can cause EHEC O157:H7 infections in humans.  
 
1.3. EHEC and Cattle 
 Although EHEC O157:H7 can colonize a number of different species, including 
sheep, dogs, some birds, and some wild animals, beef and dairy cattle are still 
considered the major reservoir for infection risk to humans (Griffin and Tauxe 
1991; Armstrong, Hollingsworth et al. 1996; LeJeune, Besser et al. 2001).  
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Cattle can carry EHEC O157:H7 for different lengths of time (Lim, Yoon et al. 
2010). Cattle can be colonized by EHEC O157:H7 at the terminal rectum mucosa 
and shed the bacteria for 3-12 months or even longer. Different factors such as 
age, diet and immunity play roles in the shedding time frame.  EHEC O157:H7 is 
more frequently isolated from cattle during warmer months of late summer and 
early fall, and not surprisingly, this is the season when the most human infections 
take place (Armstrong, Hollingsworth et al. 1996; Elder, Keen et al. 2000).  
Shedding of the bacteria by cattle for more than 12 months is a long period of 
time. This extended period of colonization in cattle can increase bacterial 
contamination of the environment, beef related products, and the other cattle in 
the herd that are not colonized by the bacteria.  
EHEC O157:H7 can easily be spread by the carrier cattle. Although ground beef 
is the main route for the infection in humans, cattle manure containing EHEC 
O157:H7 can be washed into the water supply and thus may contaminate water 
used for drinking, crop irrigation, vegetable and fruit production, and be 
transmitted to other animals that act as vectors. In fact, numerous EHEC O157:H7 
outbreaks in humans have been associated with the consumption of vegetables 
such as lettuce, radishes, alfalfa sprouts, and spinach (Fukushima, Hashizume et 
al. 1999; Ferguson, Scheftel et al. 2005; Maki 2006). Based on all this knowledge, 
some investigators stated that strategies that control the EHEC O157:H7 before it 
enters into the food chain would greatly decrease environmental contamination 
(Hancock, Besser et al. 2001). In particular, preventing or reducing EHEC 
O157:H7 colonization of cattle intestine, perhaps by vaccination, could result in a 
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decreased potential for environmental contaminations as well as lower the risks 
for contamination of beef and diary products. Therefore, vaccination of cattle has 
the potential to decrease EHEC O157:H7 infections in humans.  
 
1.4. Virulence Factors of EHEC O157:H7 
1.4.1. Locus of Enterocyte Effacement  
The locus of enterocyte effacement (LEE) is an approximately 43 kb 
pathogenicity island found in EPEC and EHEC.  EPEC has a smaller LEE region 
than EHEC that is approximately 35 kb (Yoon and Hovde 2008). The LEE region 
includes three different sections that encode five different operons. LEE1, LEE2, 
and LEE3 operons encode the genes responsible for type three secretion systems 
(TTSS).  The second section includes the LEE5 operon which encodes the genes 
responsible for bacterial adhesion, intimin and translocated intimin receptor (Tir). 
The third section includes the LEE4 operon that encodes the genes for E. coli 
secreted proteins, for example, EspA, EspB and EspD.  
 
1.4.2. Intimin  
Intimin or Eae (E. coli attaching and effacing protein) is a 94kDa outer membrane 
protein that mediates intimate attachment of the bacteria to the host epithelial cell 
(Donnenberg, Tzipori et al. 1993). This intimate attachment can cause attachment 
and effacement (A/E) lesion formation on the host intestinal epithelium 
(Donnenberg, Tzipori et al. 1993). A/E lesion formation was first described in 
EPEC (Jerse, Yu et al. 1990; Jerse and Kaper 1991) and it is characterized by 
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adherence of the bacteria to the intestinal epithelium cells and damage to 
microvilli on them. It also causes pedestal-like formation by the accumulation of 
actins in the epithelial cell underneath the attached bacteria. A/E lesion formation 
disrupts the tight junctions and causes diarrhea (Agin, Zhu et al. 2005; Guttman, 
Li et al. 2006). Frankel, Candy et al., (Frankel, Candy et al. 1994; Frankel, Candy 
et al. 1995) showed that the highly divergent C-terminal region of the intimin 
binds to its receptor, Tir. After Tir is translocated into the host cells by the type III 
secretion system, it incorporates itself into the intestinal epithelium with its 
intimin binding domain displayed on the intestinal cell surface. Subsequently, 
close interaction between intimin and Tir recruit actin within the epithelial cells 
and leads to A/E lesion formation. Although the most severe cases of infection are 
due to the production of Shiga toxin, close association of the bacteria and the 
forming of an A/E lesion is the beginning of the bacterial colonization and Shiga 
toxin release.  
In addition to the intimin/Tir interaction, intimin can interact with a host cell 
surface protein called nucleolin (Sinclair and O'Brien 2002). Both Tir and 
nucleolin bind to the carboxy-terminal domain of intimin (Frankel, Candy et al. 
1994; Frankel, Candy et al. 1995; Sinclair and O'Brien 2002). Based on these 
observations we can conclude that the carboxy-terminal domain of intimin is very 
important in the intimin host-cell interaction. 
Since the intimin is an important adherence factor for E. coli O157:H7, a vaccine 
designed target intimin in order to block the intestinal adherence of the bacteria is 
feasible. Furthermore, antibodies specific to intimin can block adherence of 
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bacteria to cultured cells and intestinal mucosa (Gansheroff, Wachtel et al. 1999; 
Dean-Nystrom, Gansheroff et al. 2002). This is a strong indication that intimin is 
an attractive candidate for the development of an EHEC O157:H7 vaccine. Thus, 
a variety of approaches are being studied as possible vaccination strategies 
including plant-derived vaccines (Judge, Mason et al. 2004). 
 
1.4.3. The pO157 
The pO157 is a large plasmid which varies from 92 Kb to 104 Kb and it is 
contained by most of the EHEC O157:H7 strains. The complete sequence of this 
plasmid was published in 1998, where it was explained that there are 100 open 
reading frames (ORFs) (Burland, Shao et al. 1998; Makino, Ishii et al. 1998). 
Presumably, 32 proteins are involved in the pathogenesis of E. coli O157:H7. 
Since pO157 encodes potential virulence factors such as hemolysin (ehx), catalase 
peroxidase (katP), and a serine protease, it may play an important role in the 
pathogenesis of EHEC.  However the role of pO157 in the pathogenesis of E. coli 
O157:H7 is not fully understood.  
 
1.4.4. Shiga toxin 
 Shiga toxins (Stx) are produced by enteric pathogens such as S. dysenteriae 
serotype 1 and EHEC. In the 1890s after an epidemic in Japan, S. dysenteriae 
(Shiga’s bacillus) serotype 1 was described by Kioshi Shiga (Shiga 1898; Trofa, 
Ueno-Olsen et al. 1999). In 1903, shortly after this discovery, Conradi described 
that an extract from the Shiga’s bacillus paralyzed and killed rabbits (Conradi, 
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1902:). A similar finding was independently reported by Neisser and Shiga 
(Neisser and Shiga, 1903). In the mid 1970s the toxin was characterized in more 
detail by different groups (Keusch and Jacewicz 1975; O'Brien, Thompson et al. 
1977) and in 1977 O’Brien and colleagues reported that certain strains of E. coli 
produce a toxin that can be neutralized by anti-Stx  (O'Brien, Thompson et al. 
1977). Since then this specific toxin from E. coli was called Shiga-like toxin. In 
the same year, Konowalchuk (Konowalchuk, Speirs et al. 1977) reported that 
certain diarrheagenic E. coli produces a toxin called Vero toxin, which can kill 
Vero (African green monkey kidney) cells.  In 1983, O’Brien et al (O'Brien, 
Lively et al. 1983) reported that Shiga-like toxin produced by E. coli O157:H7 
was responsible for causing an outbreak in the United States, and that this Shiga-
like toxin was the same as Vero toxin. Although some researchers use the name 
“Shiga toxin” for the E. coli O157:H7 toxin, some still use either “Shiga-like 
toxin” or “Vero toxin” for Shiga toxins from E. coli O157:H7. It this work I will 
use the term “Shiga toxin” (Stx). 
There are two main types of Shiga toxins associated with Shiga toxin-producing 
E. coli (STEC): Shiga toxin 1 (Stx1) and Shiga toxin 2 (Stx2).  Stx1 differs from 
the toxin produced by S. dysenteriae type 1 by only one amino acid in the A 
polypeptide (O'Loughlin and Robins-Browne 2001). On the other hand, Stx1 and 
Stx2 share approximately 56% identity at the amino acid sequence level 
(Johannes and Romer 2010). STEC can also produce Stx1 and variants (Stx1b and 
Stx1c), Stx2 variants (Stx2c, Stx2d, Stx2e and Stx2f) or combinations of different 
variants.  
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Stx is one of the major virulence factors of EHEC, and belongs to the AB5 toxin 
family consisting of an A subunit (32kDa) and five identical B subunits (7.7kDa). 
The A subunit is composed of a 27kDa enzymatically active A1 subunit and a 
5kDa structural A2 subunit.  The A1 subunit has N-glycosidase activity and it 
cleaves a single adenine residue from the 28S ribosomal RNA of the 60S 
ribosome. After the depurination step,  peptide elongation stops, since elongation 
factor 1-dependent aminoacyl transfer RNA is inhibited (Cherla, Lee et al. 2003). 
The A2 subunit associates with the A1 subunit via a disulfide bond and it links the 
A1 subunit to the B subunit pentamers by noncovalent associations (O'Loughlin 
and Robins-Browne 2001; Lim, Yoon et al. 2010). In addition, the B subunit of 
Shiga toxin (StxB) pentamer binds to its receptor, the globotriaosylceramide 
(Gb3), with the exception of Stx2eB which binds to Gb4 instead of Gb3. 
 
1.5. Shiga toxin and the HUS 
In 1955, HUS was described by Gasser and colleagues (Gasser, Gautier et al. 
1955), who reported a serious case of five children with hemolytic anemia, 
thrombocytopenia (low platelet count), and small vessel renal thrombi (Gasser, 
Gautier et al. 1955). However, the key association between an E. coli O157:H7 
infection and the HUS was discovered by Karmali et al. in 1983 (Karmali, Petric 
et al. 1983),  who reported sporadic cases of HUS associated with an E. coli toxin, 
and they realized this toxin was lethal to cultured Vero cells. A week after this 
report, Riley described two clusters of patients with bloody diarrhea, and also 
reported a linkage between this event and undercooked hamburgers. Many of the 
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patients in these clusters had E. coli O157:H7 in their stools. (Riley, Remis et al. 
1983)Shortly after, O’Brien and co-workers reported an association between E. 
coli O157:H7 toxin and the toxin of S. dysenteriae serotype 1 (O'Brien, Lively et 
al. 1983). 
Renal injury in D+HUS is caused by Stx. After ingesting the food contaminated 
with E. coli O157:H7, bacteria passes trough the acidic stomach environment and 
attaches to the intestinal epithelial cells (Bielaszewska and Karch 2005). Then Stx 
is translocated across the intestinal epithelium into circulation by binding the 
polymorphonuclear leukocytes. When Stx arrives at target organs. it binds to Gb3 
molecules displayed on the target cell surface via its B subunit and increases 
cytokine expression which in return damage the target cells (Ray and Liu 2001).  
 
1.6 Diagnosis 
The very first selective medium for screening and isolation of E. coli O157:H7 
was the sorbitol MacConkey agar (SMAC). If there is a possibility that a patient is 
infected with EHEC O157:H7, a stool specimen is collected and tested for the 
organism. The number of excreted pathogens per gram of feces rapidly decreases 
in a few days after infection. Hence, stool samples should be obtained and tested 
as soon as possible. Early in the course of the disease, samples are plated on 
SMAC, which contains 1% sorbitol instead of 1% lactose.  Since EHEC O157:H7 
is unable to ferment sorbitol rapidly; it forms colorless colonies on SMAC. 
Therefore, it can be distinguished from most of the remaining intestinal E. coli 
strains that ferment sorbitol and form pink colonies (Mead and Griffin 1998; 
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Karch, Bielaszewska et al. 1999; Kehl 2002). Other tests can also be done to 
identify EHEC O157:H7 (Ochoa and Cleary 2003). Enzyme-linked immunoassay 
(ELISA) kits are available for fast screening of fecal samples containing the O157 
antigens. The ELISA test is more sensitive compared to SMAC, but it only 
detects E. coli O157. PCR assays are also used to detect E. coli O157:H7 major 
virulence genes. PCR assays are commonly based on Stx genes and EHEC 
O157:H7 specific eae (intimin) DNA sequences (Bai, Shi et al. 2010). Positive 
results by ELISA or PCR assay should also be confirmed by culture.  
 
1.7. Recombinant Subunit Vaccines 
Infectious diseases cause a 45% mortality in low-income countries (Arntzen, 
Plotkin et al. 2005), and it is well known that vaccines are the most effective way 
of combating infectious diseases both in humans and animals. Traditional 
vaccines consist of live, killed, or attenuated pathogens. However the attenuated 
pathogen used as a vaccine can cause severe disease in immunosuppressed 
individuals, such as people suffering from HIV/AIDS or malnutrition. On the 
other hand, recombinant vaccines can offer safer options for both healthy and 
immunosuppressed individuals, since no pathogens are involved (Yusibov and 
Rabindran 2008).  
In the past 30 years, there have been many different approaches applied for 
vaccine development and manufacturing, although innovative and new methods 
are still in demand. Recombinant subunit vaccines can be produced in different 
hosts including E. coli, yeast, mammalian cells, insect cells, and plants. For 
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recombinant antigen expression, the gene that encodes a protective antigen is 
expressed in the host, and the resulting recombinant protein is purified and 
administered as a vaccine. Each type of host has some advantages and some 
challenges to overcome. For example, the vaccines produced in E. coli can 
contain endotoxins and other unwanted pyrogens. In addition, complex proteins 
produced in E. coli will not undergo some eukayrote-specific post-translational 
modifications (Choi and Lee 2004). Nonetheless, recombinant proteins produced 
in bacteria offer the advantages of low cost, high scale up capacity, and short 
production timescale. The yeast expression system has some similarities to the 
bacterial expression system, including the use of relatively inexpensive growth 
medium and the high scale-up capacity. Yeast expression has one great advantage 
over bacterial expression: yeast is able to fold and assemble complex eukaryotic 
proteins. However, protein glycosylation can be incorrect, since the yeast glycan 
structure is different than those found in mammalian cells (Romanos, Scorer et al. 
1992).  
Mammalian cells are another alternative for subunit vaccine production. Although 
complex recombinant proteins can fold correctly, the maintenance of mammalian 
cells is very costly and it is hard to scale up. An additional disadvantage of the 
mammalian cells system for subunit vaccine production is that they can carry 
oncogenic agents and pathogens. The insect cell system shares some of the 
disadvantages of mammalian cells for the production of subunit vaccines. 
Plant expression systems are an alternative to the other systems discussed above 
and are emerging as an economical substitute for fermentation-based expression 
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systems for producing of subunit vaccines (Mason and Arntzen 1995; Sojikul, 
Buehner et al. 2003; Mor, Mason et al. 2004). Plant derived recombinant vaccines 
offer some advantages over the traditional vaccines, including lower production 
cost and higher production volume, speedy scalability, higher safety (free of 
human pathogens), and ability to assemble complex eukaryotic proteins (Ma, 
Drake et al. 2003; Thanavala, Huang et al. 2006).  As in mammalian cell 
expression systems, complex recombinant proteins expressed in plants can fold 
correctly and undergo post-translational modification. However, unlike the 
mammalian cell system the plant expression system does not require the 
manufacturing and operation of expensive fermenters, employment of highly 
skilled workers and use  of costly culture media (Yusibov and Rabindran 2008). 
In addition, plants can be grown locally using inexpensive traditional agriculture 
(Goldstein and Thomas 2004).  
Since plant-derived vaccines were first described by Mason et al. (Mason, Lam et 
al. 1992) different research groups all over the world began to investigate the use 
of plants for vaccine development and today there is a long list of recombinant 
proteins produced in a variety of plant systems (Mason, Warzecha et al. 2002; 
Ma, Drake et al. 2003; Tiwari, Verma et al. 2009). Although there are many 
different types of plants have been used as hosts for production of plant derived 
vaccines, tomato has some advantages over the other plant hosts. The culture of 
tomatoes is relatively simple and well established, and tomato plants have a high 
biomass fruit yield, approximately 68,000 kg per hectare (Ma, Drake et al. 2003; 
Alvarez and Cardineau 2010). The fact that tomato produces an edible fruit is 
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another advantage for the use of this plant as a plant derived vaccine production 
host, particularly for the development of orally-delivered vaccines. The short 
shelf-life of the fresh tomato fruit can be overcome by freeze-drying and 
pulverizing the fruits (Rigano and Walmsley 2005).  
To conclude, vaccine production in plants has now been proven to be successful. 
In addition, several successful human clinical trials accomplished with plant-made 
vaccines have shown the potential of using this technology for vaccine production 
(Tacket, Mason et al. 1998; Kapusta, Modelska et al. 1999; Yusibov, Hooper et 
al. 2002; Tacket, Pasetti et al. 2004; Thanavala, Mahoney et al. 2005; Thanavala, 
Huang et al. 2006).  
After taking into consideration of all the reasons previously stated, we decided to 
use the plant system to develop a vaccine candidate to prevent E. coli O157:H7 
intestinal attachment in cattle. We expressed the carboxy-terminal one-third of 
intimin protein in tomato plants and demonstrated that this plant-derived vaccine 
candidate was immunogenic in mice. We also used bacteria for expression of 
vaccine antigens. We expressed StxB1, carboxy-terminal third of intimin (IntC) 
and StxB1-IntC fusion protein in bacteria and we confirmed the immunogenicity 
of them in mice. 
 
1.8. Specific aims of the dissertation 
One of the hypotheses proposed in this dissertation is that when the C-terminal 
domain of the intimin protein is expressed in plants and used to immunize 
animals, a specific immune response will be induced. We hypothesized that 
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immunized animals infected with EHEC O157:H7 will have a decreased duration 
of intestinal colonization by this bacteria.  
A second hypothesis is that mice immunized with purified StxB1-IntC fusion 
protein expressed in E. coli will produce stronger immune responses than mice 
immunized with either purified IntC or StxB1 alone. To test these hypotheses, I 
pursued the following steps. First, I successfully expressed IntC protein in tomato 
plants to be used as antigen in animal immunizations. Second, I purified the IntC 
expressed in two different expression systems: bacteria and plants. Third, I 
expressed StxB1-IntC fusion protein in bacteria and purified the protein. Fourth, I 
tested the immunogenicity of the purified antigens in mice before challenging 
them with EHEC O157:H7 to evaluate the duration of bacterial shedding. 
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Chapter 2 
PLANT DERIVED VACCINE TO PREVENT ESHERICHIA COLI O157:H7 
INTESTINAL ATTACHMENT 
Abstract 
In the United states, Escherichia coli serotype O157:H7  (E. coli O157:H7) is the 
most common cause of hemolytic uremic syndrome in humans and the most 
common reason for kidney failure in children (Dean-Nystrom, Gansheroff et al. 
2002). Although different wild and farm animals can carry and spread E. coli 
O157:H7, cattle are the major reservoir of this serotype. E. coli O157:H7 
infections in humans take place after ingestion of contaminated meat or dairy 
product originating from cattle. Since the bacterial protein intimin plays a major 
role in colonization, blocking this protein would prevent the intimate bacterial 
attachment to the host, leading to a reduced bacterial colonization in the cattle and 
it would limit E. coli O157:H7 infection in humans. In this research, we used 
intimin as a candidate vaccine to prevent E. coli O157:H7 colonization in the host 
by blocking the intestinal attachment. We expressed the C-terminal domain of 
intimin in transgenic tomato and we purified it using nickel affinity 
chromatography. We used this purified intimin to immunize the mice. 
We demonstrated mice immunized mucosally with tomato-derived IntC cleared E. 
coli O157:H7 from their intestines significantly faster than those mice in other 
groups. This is a very first step towards the development of a vaccine for cattle 
that will reduce their infection by E. coli O157:H7, and thus limit the incidence of 
human infections as well. 
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1. Introduction 
Escherichia coli, especially serotype O157:H7, is a main cause of diseases 
including uncomplicated diarrhea, bloody diarrhea, hemorrhagic colitis, and 
severe hemolytic uremic syndrome (HUS) in humans world wide (Sheng, Lim et 
al. 2006). HUS induced by E. coli O157:H7 is the most common cause of acute 
kidney failure in children in the United States. However, the disease caused by 
O157:H7 bacteria is not limited to children, since all age groups can be easily 
infected (Gary Reiss 2006; (Reiss, Kunz et al. 2006). In the United States, 73,480 
infections, and 61 deaths occur per year (Mead, Slutsker et al. 1999; Yoon and 
Hovde 2008) and the cost of the infections can be up to $3.3 billion dollars 
annually (Frenzen, Drake et al. 2005).  
There are three main pathways for E. coli O157:H7 infections: food-borne, 
environmental, and person-to-person contact (Strachan, Dunn et al. 2006). 
Ruminant feces are the most common contaminants for the food-borne and 
environmental route. Although different kinds of ruminants can carry E. coli 
O157:H7, cattle are the major reservoir for infections in humans (Dean-Nystrom, 
Gansheroff et al. 2002; Judge, Mason et al. 2004; Sheng, Lim et al. 2006; 
Fremaux, Prigent-Combaret et al. 2008; Serna and Boedeker 2008). The E. coli 
O157:H7 infected cattle are a direct source of contaminated meat and dairy 
products, as well as an indirect source by the fecal contamination of soil, water, 
and vegetables(Fremaux, Prigent-Combaret et al. 2008). Dairy products and meat 
can be contaminated with cattle feces during milking and slaughtering. E. coli 
O157:H7 can survive in very diverse environments including soil, sewage, 
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different water systems, various acidic environments, and the gastrointestinal tract 
(Avery, Williams et al. 2008; Yoon and Hovde 2008). It has been shown that E. 
coli O157:H7 can survive in manure or in drinking troughs for months or years 
and still be able to colonize cattle, resulting in re-contamination of the 
surroundings (LeJeune, Besser et al. 2001; Avery, Williams et al. 2008). 
 Environmental contamination by cattle was the case in the recent multi-state 
outbreak of E. coli O157:H7 infections from spinach, which resulted in 199 
infections, 31 cases of HUS, and 3 deaths (Center for Disease and Control 
Prevention, 2006). Contamination with E. coli in meat products decreased in 
recent years because of the higher safety standards of in the meat industry. 
However, the recent large multi-state E. coli O157:H7 outbreaks caused by the 
ingestion of infected spinach showed that a prevention of these infections is 
urgently needed.  
Preventing the infection is extremely important, because antibiotic treatments 
after the infection are unreliable. There are some conflicting results on antibiotic 
usage in cases of HUS caused by E. coli O157:H7. Unfortunately, according to 
some studies, antibiotic treatment can increase the risk of HUS (Wong, Jelacic et 
al. 2000; Safdar, Said et al. 2002; Ochoa and Cleary 2003), and does not improve 
the outcome of the disease (Scheiring, Andreoli et al. 2008).  
One of the best strategies to reduce infection with E. coli O157:H7 in humans is 
to prevent bacterial colonization in cattle. This strategy is very well accepted by 
many researchers (Dean-Nystrom, Gansheroff et al. 2002; Judge, Mason et al. 
2004; Cataldi, Yevsa et al. 2008), who believe that it would reduce the incidence 
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of infection in humans by preventing bacterial colonization of cattle, and 
therefore, reducing food-borne and environmental contamination with E. coli 
O157:H7.  
Intimin is an E. coli O157:H7 outer membrane protein that is required for intimate 
attachment of the bacteria to the host cells and essential for attaching and effacing 
lesion (A/E lesion) formation (Donnenberg, Tzipori et al. 1993; McKee, Melton-
Celsa et al. 1995; McKee and O'Brien 1996; Dean-Nystrom, Bosworth et al. 
1998; Batchelor, Prasannan et al. 2000). A/E lesions are characterized by the 
destruction (effacement) of brush border microvilli, intimate adherence of the 
bacteria to the host cell, and cytoskeletal rearrangement of the host cell resulting 
in a pedestal like formation underneath the bacterial attachment (Moon, Whipp et 
al. 1983; Nataro and Kaper 1998). Based on that knowledge, we propose that 
antibodies against intimin could inhibit or prevent bacterial attachment in the host. 
Hence, intimin is a very promising vaccine candidate that could reduce O157:H7 
colonization in cattle. It has also been shown that suckling piglets were protected 
from colonization with EHEC O157:H7 by ingesting colostrum from intimin-
vaccinated dams (Dean-Nystrom, Gansheroff et al. 2002). Judge et. al. (Judge, 
Mason et al. 2004) demonstrated that mice primed with plant-derived intimin C-
terminal domain (IntC) and orally boosted with plant-derived IntC showed a 
decrease in bacterial shedding in their feces after they were challenged with E. 
coli O157:H7. Cataldi et al. (2008), demonstrated that intimin is a good potential 
vaccine candidate These examples provide evidence that vaccination with intimin 
  20 
is a potential strategy for prevention of E. coli O157:H7 colonization in cattle. 
Hence, we used the E. coli O157:H7 intimin protein as a vaccine candidate. 
Since Mason et al. (Mason, Lam et al. 1992) reported the expression of hepatitis 
B surface antigen different research groups all over the world began to investigate 
the use of plants for potential vaccine development, and vaccine production in 
plants has now shown a great potential (Haq, Mason et al. 1995; Mason, Ball et 
al. 1996; Mason, Haq et al. 1998; Tacket, Mason et al. 1998; Tacket and Mason 
1999; Judge, Mason et al. 2004; Alvarez, Pinyerd et al. 2006; Wen, Teel et al. 
2006b). Plant expression systems offer several advantages compared to other 
expression systems, including lower risk of contamination with human pathogens, 
larger scaling up capacity, cost-effective production (Thanavala, Huang et al. 
2006; Mestecky, Nguyen et al. 2008). In addition, the several human clinical trials 
accomplished with oral delivery of plant-made vaccines have shown the potential 
of using the plant-made vaccine technology (Tacket, Mason et al. 1998; Kapusta, 
Modelska et al. 1999; Yusibov, Hooper et al. 2002; Tacket, Pasetti et al. 2004). 
Thus, we developed a candidate plant-derived vaccine to prevent E. coli O157:H7 
intestinal attachment by expressing the IntC protein in tomato plants, and showed 
that it was immunogenic in mice. 
 
2. Materials and methods  
2.1 Plasmids 
Tomato plants were transformed using plasmids pNR49 and pNR50 (Judge, 
Mason et al. 2004). pNR49 contains a plant-optimized C-terminal 281 amino 
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acids of intimin from E. coli O157:H7 strain 86-24 (Genbank Z11541) with a 6-
His tag added at the N-terminus, and the soybean vspA N-terminal signal peptide 
sequence obtained from plasmid pBTI210.4. The construct was reported to 
contain the C-terminal 281 amino acids of intimin (Judge, Mason et al. 2004), but 
our sequencing showed that it actually contains 281 intimin residues. pNR50 
(Judge, Mason et al. 2004) is similar to plasmid pNR49 except that does not 











 Figure 1. IntC expression constructs pNR49 and pNR50 were used for 
recombinant protein expression in tomato plants. The CaMV 35S promoter and 
soybean vspB 3’ region flank the IntC coding sequence. Neomycin 
phosphotransferase II used to express kanamycin resistance in transgenic plants. 
The VspA signal peptide from soybean vegetative storage protein A was 
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2.2 Stable transformation of tomato 
The Agrobacterium-mediated transformation protocol was modified from 
Walmsley et al. (Walmsley, Alvarez et al. 2003). Tomato cotyledons from 
Lycopersicon esculentum variety Tanksley TA234 was used for stable 
transformation. Tomato seeds were first sterilized in 20% Clorox (Commercial 
bleach, active ingredient is 5.25% NaOCl) for 20 minutes and rinsed with sterile 
distilled water three times. After sterilization, seeds were placed on half-strength 
Murashige and Skoog (MS) medium (50 mg/l myo-inosytol, 2 mg/l thiamine 
HCL, 0.5 mg/l pyridoxine HCl, 0.5 mg/l nicotinic acid, 10 g/l sucrose, 8 g/l Difco 
bacto agar, pH 5.8) and left to germinate. Cotyledons were excised from 
germinated seedlings before the first true leaves appeared. Cotyledons were cut 
into small squares (approximately 1 cm2) and incubated in a suspension of 
Agrobacterium tumefaciens LBA4404 containing a binary vector, either pNR49 
or pNR50, for 10 minutes on a shaker at room temperature. Cotyledon explants 
were then transferred with adaxial side up into 2Z selection medium (4.3 g/l MS 
salts, 20 g/l sucrose, 100 mg/l myo-inosytol, 2 mg/l glycine, 10 mg/l nicotinic 
acid, 0.5 mg/l pyridoxine HCL, 0.5 g/l thiamine HCL,  0.5 mg/l  folic acid, 0.5 
mg/l  d-biotin, 5.2 g/l agar, 300 mg/l timentin, 100 mg/l kanamycin, pH 5.8-6) . 
Cotyledon explants were transferred to 2Z selection medium every three weeks 
until shoots began to appear. Shoots were then excised and transferred to rooting 
medium (4.3 g/l MS salts, 30 g/l sucrose, 2 mg/l glycine, 10 mg/l nicotinic acid, 
0.5 mg/l pyridoxine HCL, 0.5 g/l thiamine HCL, 0.5 mg/l  folic acid, 0.5 mg/l  d-
biotin, 8 g/l bacto-agar, 300 mg/l timentin, 100 mg/l kanamycin, pH 5.8-6)  
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2.3 Protein extraction from fresh leaves, fresh fruits and freeze- dried fruits 
Approximately 300 mg fresh leaves or fresh fruit were placed into 2 ml 
Fastprep® tubes (Fisher Scientific, PA) and frozen in liquid nitrogen. 
Approximately 0.03 mg of pulverized freeze-dried tomato fruit was placed into 2 
ml Fastprep® tubes. All of the samples were suspended in 1 ml extraction buffer 
(100mM Tris pH8, 100mM NaCl, 1mM EDTA, 0.01% Triton X-100, 10µg/ml 
leupeptin) and homogenized in a Fastprep® machine (FP120 BIO101 Savant, Lab 
Central B.V., Haarlem, The Netherlands)  for 40 seconds at speed 4.  The samples 
were centrifuged at 20,000xg for 30 minutes at 4˚C, and the supernatants 
transferred to clean 1.5 ml tubes and tested by Bradford assay (Bradford 1976) for 
total protein using bovine serum albumin (BSA) as the reference standard, and 
tested for intimin expression (below). 
 
2.4. Enzyme-linked immunosorbent assay (ELISA) for intimin 
The expression of IntC protein in transgenic tomato plants was measured by 
ELISA. All antibodies were diluted in 1% dry milk (DM) in phosphate buffer 
saline (PBS) containing 0.05% Tween 20 (1% DM /PBST), except the goat anti-
intimin antibody, which was diluted in PBS. High binding polystyrene EIA/RIA 
96 well micro plates (Corning, NY) were incubated with goat anti-intimin 
antibody  (Kindly provided by Dr. Alison O’Brien) diluted 1:3000 for 2 hours at 
37˚C. ELISA plates were washed three times with PBST and blocked with 5% dry 
milk/PBST overnight at 4˚C.  The next day, the ELISA plates were washed three 
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times with PBST. Dilutions of bacterial intimin  (Kindly provided by Dr. Alison 
O’Brien) and plant extracts were diluted in 1% DM/PBST, added to the plates, 
and incubated for 2 hours at 37˚C. Following three washes with PBST, the plates 
were incubated with rabbit anti-intimin antibody at a 1:5000 dilution, for 2 hours 
at 37˚C. Following  three washes with PBST, horseradish peroxidase (HRP) 
labeled goat anti-rabbit antibody (1:10000 dilution) was added to the wells, and 
the plates were incubated for 1 hour at 37˚C. The HRP substrate in the ECL Plus 
kit (Amersham Biosciences, Piscataway, NJ) was used to develop color as per the 
manufacturer’s instructions. The optical densities at 450nm (OD450) of the 
samples were read on a microtiter plate reader (MRX-tc, Dynex technologies, 
Chantilly, VA).   
A standard curve was generated from the bacterial intimin reference standard 
readings, and used to calculate the IntC concentration in the plant samples. 
 
2.5. Western blot analysis 
The protein extracts were obtained as it was described in section 2.3. The content 
of total soluble proteins (TSP) was calculated using Bradford assay (Bio-Rad, 
Hercules, CA), using BSA as the reference standard. Equal amounts of TSP from 
each plant extract was calculated and 6x SDS gel loading buffer (300mM Tris-
HCl, pH 6.8, 600mM dithiothreitol, 12% SDS, 0.6% bromophenol blue, 60% 
glycerol) was added to the samples before boiling them for 15 minutes and 
placing them on ice. Samples were centrifuged for 5 seconds at 16,000xg and 
loaded into a precast SDS polyacrylamid gel (Bio-Rad, 12% Tris-HCl separating, 
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4% stacking). The gel was run at 35mA for 2 hours using a Tris-glycine running 
buffer (25mM Tris, 250mM glycine and 0.1% SDS), and the proteins were 
electrotransferred onto a PVDF membrane at 80V for 2 hours. The membrane was 
blocked overnight at 4˚C, and the following day it was blocked in 5% DM/PBST 
on a shaker at room temperature. The membrane was washed six times in PBST 
for 15 minutes each, and then incubated with rabbit polyclonal antibody against 
intimin (kindly provide by Dr. Alison O’Brien) diluted 1:8000 in 1% DM/ PBST 
for 1 hour at 37˚C . The membrane was washed four times in PBST for 15 
minutes each, and then incubated with HRP conjugated goat polyclonal anti-
rabbit IgG (Sigma-Aldrich, Saint Louis, MO) at a 1:10000 dilution in 1% DM/ 
PBST. The ECL plus kit (Amersham Biosciences, Piscataway, NJ) was used to 
detect the specific protein according to the manufacturer’s instructions. Purified 
bacterial  purified intimin (kindly provide by Dr. Alison O’Brien) was used as a 
positive control and a wild type tomato plant extract as a negative control.  
 
2.6. Tomato fruit processing for animal trials 
Freshly collected tomato fruits from the same plant were pooled and kept at -
20°C. Frozen fruits were cut into small pieces using a deli- slicer and then freeze-
dried using a FreeZone Freeze Dry system (Labconco) for at least 4 days. Freeze-
dried fruits were ground into a powder, vacuum-sealed in plastic with a vacuum 
food sealer and stored at room temperature or collected in 50 ml conical tubes and 
saved at room temperature. 
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2.7. Protein purification from freeze-dried fruits 
Approximately, 5 g of freeze-dried powdered red tomatoes were slowly placed 
into a cold mortar containing liquid nitrogen and the mixture was ground until a 
fine powder was obtained. 50 ml extraction buffer (20mM sodium phosphate, 
0.5M sodium chloride, 10 µg/ml leupeptin and 10mM imidazole) was added to 
the fine powder, transferred into a 50ml tube and centrifuged at 10000xg for 45 
minutes. The supernatant was transferred to a clean 50 ml tube and the 
centrifugation step repeated. Finally, the supernatant was filtered through a 
membrane and added to a His Trap Hp Column (GE Healthcare life Sciences, 
Piscataway, NJ) according to the manufacturer’s instructions.  
 
2.8 Deglycosylation of purified IntC from tomato fruit 
Purified His-tagged IntC from freeze-dried tomato fruit was treated with 
trifluoromethanesulfonic acid (TFMS) (Prozyme, Hayward, CA) and PNGase F, 
PNGase A, and Endo H (New England Biolabs, Ipswich, MA) according to 
manufacturer’s instruction. Purified plant-derived Intimin and bacterial-derived 
Intimin were denatured in Glycoprotein Denaturing Buffer (0.5% SDS, 40mM 
dithiothreitol) at 100 °C for 15 min. Samples were centrifuged at 2,000 × g for 1 
min, and the supernatant was used for endoglycosidase digestions. Approximately 
10μg of the denatured bacterial- and plant-derived Intimin was digested with 
PNGase F (1000 U) or Endo H (2000 U) at 37 °C for 3 h. The samples were then 
analyzed by Western blotting. 
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2.9. Animal immunization 
Twenty-four-week-old female BALB/c mice were separated into three different 
groups of six animals each. On day 0, all the mice were primed intraperitoneally 
(IP) with 0.5µg purified bacterially derived IntC (See chapter 3), including the 
negative control mice (group 1). TiterMax Gold (TiterMax, GA) was used as an 
adjuvant according to the manufacturer’s instructions. On week 3, the mice in 
group 2 were boosted intranasally (IN, mice held by their scruff and 5µl of PBS 
containing purified intimin was delivered to each nostril) with 4µg of tomato-
derived IntC supplemented with 10µg of cholera toxin (CT, Sigma-Aldrich, Saint 
Louis, MO) as an adjuvant, and  the mice in group 3 (positive control) were 
boosted IP with 0.5µg tomato-derived IntC supplemented with TiterMax Gold. 
The mice in group 2 were boosted again at weeks 7 and 14 with IN delivery of 4 
and 30µg of tomato-derived IntC supplemented with 10µg CT, respectively. The 
mice in group 3 were boosted IP with 0.5µg tomato-derived IntC supplemented 
with TiterMax Gold at week 7. Blood samples were collected from the 
submandibular vein and incubated at room temperature for 10 minutes to let the 
blood coagulate, and centrifuged at 3000xg for 10 minutes. The sera were 
transferred to clean tubes and saved at -20˚C until samples were tested by ELISA. 
Fecal pellets and vaginal lavages were also collected from individually housed 
mice and saved at -20˚C until they were tested by ELISA to detect specific IgA 
titers. Proteins were extracted from fecal pellets using 1ml extraction buffer 
(10µg/ml leupeptin, 0.1% Tween 20 in PBS) per 100mg of fecal pellets. Samples 
were first kept at 4˚C for 20 minutes before a 1 min homogenization by Bullet 
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Blender homogenizer (Next Advance Inc., Averill Park, NY). Homogenized 
samples were centrifuged at 20,800xg in an Eppendorf microcentrifuge 5417R 
(Eppendorf, Hauppauge, NY) for 10 minutes at 4˚C. The cleared supernatants 
were collected and analyzed by ELISA. Vaginal lavage (vaginal opening of the 
mice were washed using round needle and syringe) samples were mix very well 
by vortexing and centrifuged in an Eppendorf Microcentrifuge 5417R at 17900xg 
for 10 minutes at 4˚C. 
 
2.10. ELISA to determine IgG1 and IgG2 titers in mouse serum, and IgA titer in 
feces and vaginal lavages  
ELISA was used to measure antigen-specific antibody titers in the  biological 
samples. High binding polystyrene EIA/RIA 96-well microplates (Corning, 
Glendale, AZ) were coated with 50ng bacterial IntC protein (purified in our 
laboratory) in PBS. Plates were then incubated at room temperature for 4h and 
then overnight at 4˚C. On the following day, plates were washed with PBST (PBS 
pH 7.4 with 0.05% Tween-20) and then blocked with 5% skim milk in PBST (5% 
PBST) for 1 h at 37˚C.  After another three washes with PBST, sera were serially 
diluted two-fold in the ELISA plate and incubated for 1 h at 37˚C. Plates were 
washed three times with PBST, before incubation with HRP-conjugated goat anti-
mouse IgG1 at dilution 1:2,500 in 1% PBST for IgG1 detection, or goat anti-
mouse IgG2a at dilution 1:2,500 in 1% DM/ PBST for IgG2a detection. For 
detection of IgA in fecal extracts and vaginal lavages, HRP-conjugated goat anti-
mouse IgA was used at dilution 1:1,000 in 1% DM PBST. Plates were washed 
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three times with PBST and the color developed with TMB peroxidase substrate 
(Bio-Rad, Hercules, CA). The enzymatic reaction was stopped with 1N H2SO4 
and the absorbance was read at 450nm in an Elisa plate reader (MRX-tc, Dynex 
technologies, Chantilly, VA).  Titers were calculated as the highest dilution factor 
of the serum that produced an absorbance reading of 0.1 at 450nm after 
subtracting non-specific absorbance reading from non-treated mice.  
 
2.11. Bacterial Challenge  
Two weeks after the last boost, mice were fasted overnight and the water was 
removed from the cages 4 hours prior to the bacterial administration. 
Streptomycin resistant EHEC O157:H7 strain 86-24 Strr (Melton-Celsa, Rogers et 
al. 1998)was plated one night before 2-3 colonies were selected to prepare a liquid 
culture.  Twenty-five ml of LB culture containing 100µg/ml streptomycin was 
shaken at 37˚C for 3 hours. The bacterial culture was centrifuged and re-
suspended with freshly prepared, filter-sterilized 2.5 ml of 20% sucrose. A total of 
two doses were administered 4 hours apart and in each dose mice were fed with 
108-109 colony forming units (CFU) of bacteria. Following the challenge, fecal 
pellets were collected from individually caged mice. 
 
2.12. Statistical Analysis  
The non-parametric Kruskal-Wallis test with Dunn’s Multiple Comparison post 
test were used to compare the levels of antigen-specific IgG1, IgG2a, and IgA 
antibodies in immunized mice. A one-way ANOVA with a Bonferroni’s post test 
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was used to compare the logarithms of CFU in feces from mice immunized using 
the different treatments previously described (section 2.9), and then challenged 
with EHEC O157:H7 strain. All the statistical analyses were performed using 
software Prism 5 (GraphPad). 
 
3. Results 
3.1. Stable Transgenic Plants 
Out of 100 explants, only 53 explants developed healthy plantlets in kanamycin 
selection media, of which 28 expressed IntC protein that was detected using 
ELISA and Western blot. Of these 28 plants, pNR49-derived lines 49-3, 49-4b, 
and pNR50-derived line 50-7 were selected as elite lines because of their levels of 
IntC expression. Elite lines were transferred from selective media into soil and 
grown in a green house. Tomato fruits were then collected and freeze dried as 
previously described. 
The screening of putative transgenic plants was performed by intimin-specific 
ELISA of leaf extracts. Tomato plants transformed with pNR49 expressed higher 
levels of IntC (1.78% IntC per TSP) than those transformed with plasmid pNR50 
(0.03% IntC per TSP) (Fig 2).   
 
3.2. IntC expression in freeze-dried tomato fruits 
The expression levels of IntC in freeze-dried tomato fruits were tested using 
intimin-specific ELISA. In selected tomato plants from two different first and 
second generation lines, IntC expression in red fruits was better than in the green 
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fruits. In the first generation line 49-3, the expression of IntC was 0.52 and 0.40 
mg per gram of freeze-dried red and green fruit, respectively. In line 49-4b, the 
expression of IntC was 0.54 and 0.42 mg per gram of freeze-dried red and green 
tomato fruit, respectively (Fig. 3a). The second generation plants (named 49-3.6 
and 49-4b.3) expressed 1.28 and 0.72 mg of IntC per gram of freeze-dried red and 
green tomato fruit, respectively. In line 49-4b.3, IntC expression was 1.86 and 
1.55 mg per gram of freeze-dried red and green tomato fruit, respectively (Fig. 
3b). Hence, red freeze-dried tomatoes were used in subsequent studies and for the 
animal trials.  Western blot showed a strong band of 33kDa corresponding to IntC 








Figure 2. Expression of IntC in the first generation of tomato leaves. Tomato 
plants transformed with plasmid pNR49 expressed higher levels of IntC, 1.78% 
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 Figure. 3. IntC expression in the freeze dried tomato fruits from (A) T0 (primary 
transformant) elite plants and (B) T1 (second generation) elite plants. Plant names 
start with number 49 or 50 (indicting plants transformed with pNR49 or pNR50), 
followed by the line number. 
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Figure 4. Expression of IntC in freeze-dried tomato fruits in T0 and T1 elite lines. 
All samples were standardized to contain 5µg TSP. P: positive control, 100ng of 
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3.3. IntC purification from freeze-dried fruits and glycosylation analysis of IntC 
Filtered supernatants of crude fruit extracts were purified using a Ni-Sepharose 
High Performance HisTrap-HP Column (GE Healthcare, Piscataway, NJ), 
according to the manufacturer’s instructions. The expected 33kDa IntC band was 
observed both in Western blot and Coomassie-stained SDS-PAGE gel (Fig. 5a 
and 5b). 
Glycosylation of the purified IntC was not indicated, because treatment with 
trifluoromethanesulfonic acid (TFMS), PNGase F, PNGase A or Endo H did not 














 Figure 5.  Purification of IntC from tomato fruits and bacteria. (A) Coomassie-
stained gel, with 5µg antigens each lane. (B) Western blot probed with intimin-
specific antibody, with 100ng antigens. M: Molecular weight marker. 
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 Figure 6.  Deglycosylation of the purified IntC. Purified IntC from tomato and 
bacteria were treated with (A) PNGaseF or Endo H, (B) TMSF, or (C) PNGaseA,  
before loading 100ng on SDS-PAGE, blotting and probing with anti-intimin 
antibody. Untreated: same mass of antigens loaded without deglycosylation 
treatment. 
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3.4. Immunogenicity of tomato-derived IntC  
After immunization with purified IntC from tomato (Table 1), BALB/c mice 
produced intimin-specific IgG1 and IgG2a antibodies in sera. In general, mice in 
all of the immunization groups produced higher levels of intimin-specific IgG1 
than IgG2a antibodies (Fig 7a and 7b). Serum IgG1 levels raised in mice 
immunized IN with tomato-derived IntC and mice in the positive control group 
are both significantly different (P < 0.001) than mice in the negative control 
group. Intimin-specific serum IgG2a titers in both of the immunized groups were 
significantly different than mice in the negative control group (P < 0.001). Ratio 
for serum IgG1 to Serum IgG2a were also shown in table 2. Intimin-specific IgA 
titers were also detected in fecal samples from mice immunized IN with tomato-
derived IntC, but not in mice in the positive control or mice in the negative 
control group (Fig. 8a and 8b). Intimin specific fecal IgA in mice immunized with 
tomato-derived IntC was significantly different than the mice in the negative 
control group and the group immunized with bacterial intimin (P<0.01 and 
P<0.001 respectively). The mice immunized IN with tomato-derived IntC 
produced intimin-specific vaginal IgA, but neither mice in the positive or negative 
control groups raised intimin-specific vaginal IgA. (Fig. 8a and 8b).  
 
3.5. Bacterial challenge of immunized mice 
After mice were challenged with E. coli O157:H7, the shedding of streptomycin-
resistant E. coli O157:H7 strain 86-24 was evaluated for 11 days. Mice in the 
control group shed the bacteria during the entire 11 days of the evaluation period.  
Table 1. Mice immunization groups and treatments: Mice in testing group (group 
I), mice in positive control group (group II) and mice in negative control (group 
III) were primed with 0.5µg bacterial-derived purified intimin intraperitonally 
(I.P., with TiterMax as an adjuvant) and mice in group IV primed with PBS  I.P. 
(TiterMax used as an adjuvant). Mice in testing group were boosted with tomato-
derived purified intimin intranasally and mice in positive group boosted with 
bacterial-derived purified intimin intraperitonally. 
 
 
Groups Prime 1st Boost 2nd Boost 3rd Boost
Group I 0.5 µg B. Intimin I.P. 4 µg T. Intimin I.N. 4 µg T. Intimin I.N. 30 µg T. Intimin I.N.
(Testing group) (with TiterMax) (with 10 µg CT) (with 10 µg CT) (with 10 µg CT)
Group II 0.5 µg B. Intimin I.P. 0.5 µg B. Intimin I.P. 0.5 µg B. Intimin I.P.
(Positive control) (with TiterMax) (with TiterMax) (with TiterMax)
Group III 0.5 µg B. Intimin I.P.
(Negative control) (with TiterMax)
Group IV PBS I.P.
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Figure 7. Antigen-specific IgG1 (A) and IgG2a (B) elicited in mice immunized IN 
with tomato-derived IntC (Tom. IntC), immunized IP with bacterial IntC only 
(Positive), or sham-immunized with PBS (Negative).  
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Table 2. IgG1 to IgG2a ratios for the mice immunized with tomato-derived 
intimin and mice in positive control. 
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 Figure 8. Antigen-specific fecal (A) and vaginal (B) IgA raised in mice 
immunized IN with tomato-derived IntC (Tom. IntC), immunized IP with 
bacterial IntC only (Positive), or sham-immunized with PBS (Negative).  
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However, mice immunized IN with tomato-derived IntC and mice in the positive 
control group cleared the bacteria from their systems in nine and eight days, 
respectively (Fig 9). In addition, there was a significant reduction in bacterial 
shedding starting at day 5 through 8 after the challenge in mice immunized IN 
with tomato-derived IntC compared to mice in the positive control group 
(P<0.001) (Fig. 9). We did not observe any weight change or abnormal behavior 




























Figure 9. Shedding of bacteria after challenge of mice with E. coli O157:H7 strain 
86-24 Strr. Mice were immunized IN with tomato-derived IntC (Tom. IntC), 
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4. Discussion 
 
There have been previous attempts from different research groups to produce a 
vaccine to protect humans or animals from E. coli O157:H7 infection. One of the 
approaches used intimin as a vaccine candidate to prevent intestinal colonization 
in humans or animals by E. coli O157:H7 (Dean-Nystrom, Gansheroff et al. 
2002).  
In this study, we used an intimin subunit vaccine produced in tomato plants as a 
strategy to prevent intestinal colonization of E. coli O157:H7. Tomato is a good 
candidate for the production of plant-derived vaccines because it yields large 
masses of fruits and has well-established methods for industrial greenhouse 
culture and fruit processing (Alvarez, Pinyerd et al. 2006). Unfortunately, most of 
the proteins expressed in plants have a short shelf life if they are used fresh, as 
with tomato fruits (Rigano and Walmsley 2005). This problem can easily be 
solved  by freeze drying the transgenic tomato fruits (Alvarez and Cardineau 
2010). Hence, we chose to freeze-dry tomato fruits expressing IntC. We did not 
observe any degradation of IntC protein in freeze-dried tomato powder saved for a 
year in vacuum-sealed bags or 50 ml tubes at room temperature (data not shown). 
Thus, freeze-drying is an inexpensive and well-established technology that can be 
used to preserve IntC tomato fruits without recombinant protein degradation.  
Leaves from the first generation (T0) of putative transgenic tomato plants were 
tested by ELISA to confirm intimin expression. Tomato plants transformed with 
pNR49 expressed higher levels of IntC (1.78% TSP) than those plants 
transformed with pNR50 (0.03% TSP). Unlike pNR50, pNR49 has a VspA signal 
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peptide that directs the recombinant protein to be co-translationally translocated 
into the endoplasmic reticulum (ER), which resulted in higher IntC accumulation. 
Thus, we decided to continue our experiments only with tomato plants 
transformed with pNR49.  Judge et al.(Judge, Mason et al. 2004) reported similar 
findings in IntC NT-1 transgenic cell lines transformed using the same plasmid 
constructs. Unfortunately, these authors found that the pNR49 cell lines producing 
the highest levels of IntC, after several months in culture, showed bands of higher 
molecular weight than that expected for IntC, suggesting glycosylation. In 
addition, antibodies raised against the higher molecular mass IntC recognized that 
IntC species, but not the bacterially-derived IntC. For this reason, Judge et al. 
(2004) speculated that the plant cell-directed glycosylation of IntC affected the 
antibody recognition of the bacterially-derived intimin, and used the non-
glycosylated IntC derived from NT-1 cells transformed with pNR50 for mouse 
immunogenicity studies. We evaluated the tomato-derived IntC for potential 
glycosylation before the mouse studies, in order to avoid misinterpretation of the 
data. In contrast to the Judge et al. (2004) findings, our data indicate that the 
tomato-derived IntC was not glycosylated, because (a) it co-migrated on SDS-
PAGE at the same molecular mass as bacterial IntC, which is not glycosylated, 
and (b) various chemical and enzymatic deglycosylation treatments had no effect 
on its mobility (Fig. 5). 
In the mouse immunogenicity studies, we found that the tomato-derived IntC 
candidate vaccine  was immunogenic, and elicited not only intimin-specific serum 
IgG1 and IgG2a responses (Fig. 6), but also induced mucosal immune responses 
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demonstrated by the presence of intimin-specific IgA in vaginal lavages and fecal 
pellets (Fig. 8a and 8b). In addition, mice immunized IN with tomato-derived 
IntC and challenged with E. coli O157:H7 shed the bacteria for a shorter period of 
time than mice both in the positive and negative control groups, which suggests a 
reduced time of E. coli 0157:H7 intestinal colonization in mice (Fig. 9). 
Taken together, the results presented here demonstrate the high potential of a 
mucosally-delivered tomato-derived IntC as a candidate vaccine for prevention of 
E. coli O157:H7 intestinal attachment and colonization. This is the first step 
towards the development of a vaccine for cattle that will reduce their infection by 
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Chapter 3 
SHIGATOXIN B SUBUNIT-INTIMIN FUSION VACCINE TO PREVENT 
ESCHERICHIA COLI O157:H7 INFECTION  
Abstract 
E. coli O157:H7 is the most common cause of hemolytic uremic syndrome. Cattle 
represent the main reservoir for these bacteria. The E. coli O157:H7 outer 
membrane protein intimin is required for persistent colonization by this organism 
in numerous animal models that include neonatal and young calves. Thus intimin 
is a potential O157: H7 vaccine candidate for both humans and cattle. In this 
study we asked whether a fusion protein comprised of the C-terminal 1/3 of 
intimin from E. coli O157:H7 (IntC) and the Shiga toxin type 1 B subunit (StxB1) 
would enhance mucosal targeting and immunogenicity of intimin. We constructed 
and expressed the fusion protein StxB1-IntC, in which N-terminally His-tagged 
StxB1, a short linker (G4S)2 and IntC were fused in-frame. This fusion protein as 
well as individually His-tagged protein StxB1 and IntC was purified by metal 
affinity chromatography and then 0.5μg of each protein was used to prime groups 
of BALB/c mice by IP injection Mice were then boosted intranasally with 30μg of 
IntC, StxB1, or StxB1-IntC. Mice immunized with StxB1-IntC produced the 
highest levels of specific serum IgG1 and IgG2a and fecal and vaginal IgA 
antibody against IntC or StxB1 than those immunized with IntC or StxB1 alone. 
After a challenge with E. coli O157:H7, mice immunized with StxB1-IntC cleared 
the inoculated bacteria from their intestine 4 days after the challenge, versus 7 or 
10 days for bacterial clearance in mice immunized with StxB1 or IntC alone, 
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respectively. These results suggest an immunologically synergistic effect of the 
fusion protein, possibly mediated by mucosal targeting via StxB1 and/or IntC.  
 
1. Introduction 
In the United States, hemolytic uremic syndrome (HUS) associated with infection 
by enterohemorrhagic Escherichia coli (EHEC) serotype O157:H7 is the most 
common cause of acute kidney failure in children (Paton and Paton 1998). 
Disease caused by EHEC is particularly dangerous for young children and the 
elderly population (Reiss, Kunz et al. 2006).  In the United States, 73,480 cases of 
E. coli O157:H7 disease and additional ~36,740 cases of illness due to other 
serotypes of Shiga toxin-producing E. coli (STEC) are projected to occur each 
year (Mead, Slutsker et al. 1999). The impact of these infections (i.e. 
hospitalization, lost work days, etc) is predicted to cost as much as 3.3 billion 
dollars annually (Frenzen, Drake et al. 2005). Shiga toxins types 1 (Stx1) or type 
2 (Stx2) are major virulence factors of E. coli O157:H7. The prototypic Stx is 
composed of one enzymatically active (N-glycosidase) A subunit (StxA, 32 kDa) 
and five B subunits (StxB, 7.7 kDa) (Furutani, Ito et al. 1990). StxA binds non-
covalently to five identical B subunits. The pentameric StxB is responsible for 
binding to its receptor, a glybotriaosylceramide (Gb3), which facilitates entry of 
the enzymatically (N-glycosidase activity) active StxA into host cells, where the 
A1 fragment of this subunit inhibits protein synthesis (Jacewicz, Clausen et al. 
1986; Donohue-Rolfe, Jacewicz et al. 1989). 
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The EHEC genome contains a pathogenicity island called “locus of enterocyte 
effacement” (LEE) (Agin, Cantey et al. 1996). The LEE region contains five 
different operons named LEE1 to LEE5. The LEE 1, LEE2 and LEE3 operons 
encode the elements of a type III secretion system. LEE4 operon encodes some of 
the secreted proteins. LEE5 encodes the outer membrane protein intimin and its 
receptor named “translocated intimin receptor” (Tir).  LEE is responsible for 
attachment and effacement (A/E) lesion formation. The intestinal lesion caused by 
EHEC is characterized by loss of microvilli and cytoskeletal rearrangement. The 
first step for the lesion formation is intimate attachment of the bacteria to the host. 
Intimin and Tir together play an important role in this intimate attachment. Hence, 
intimin has previously been used as a vaccine candidate for prevention of EHEC 
infections (McKee and O'Brien 1996; Stakenborg, Vandekerchove et al. 2006; 
van Diemen, Dziva et al. 2007)  
In this study, we linked StxB1 (from Stx type 1) to the C-terminal third of intimin 
(IntC) to create a fusion protein (StxB1-IntC), which generated better mucosal 
and systemic immune responses in mice, as well as higher protection against 
infection with E. coli O157:H7 than either StxB1 or IntC delivered alone. We thus 
provide proof of principle that an StxB1 fusion protein is effective to develop an 
anti E. coli O157:H7 colonization vaccine candidate. Finally, we propose that 
StxB1 may be useful as a mucosal targeting molecule and/or adjuvant for the 
development of other mucosal vaccine candidates.   
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2. Materials and Methods 
2.1. Plasmids 
StxB1, which is identical to the StxB subunit from Shigella dysenteriae type 1 
(Strockbine, Jackson et al. 1988), is the binding subunit of an A1:B5 oligomer of 
Stx1. The native bacterial sequence of StxB1 (Genbank M19437;  (Strockbine, 
Jackson et al. 1988) was analyzed and a plant-optimized gene was designed that 
eliminated mRNA instability sequences and substituted plant-preferred codons 
where needed The synthetic gene was prepared by assembly PCR using 
overlapping oligonucleotides spanning the entire sequence, and it was verified it 
by DNA sequencing. The plant-optimized StxB gene was inserted into our 
standard plant expression vector pIBT210 (Haq, Mason et al. 1995) at NcoI 5’ 
and SacI 3’ to make pStxB210 (made for expression in plants).  
To make p6HStxB210, PCR using pStxB210 as template and primers N6HK (5’-
GACCATGGGAGGATCTCACCATCACCATCATCACGGTACCCCAGATTG
TGTGAC ), which incorporated a 6His tag, and VSPHT (5’-
TGAATAGTGCATATCAGCATACCTTA) produced a product that was 
digested with NcoI and BseRI. The previously constructed pIC-StxB1-D1, which 
contains an in-frame fusion of the plant-optimized StxB1 gene, a (G4S)2 linker, 
and IntC (H. Mason, unpublished) was digested with BseRI and SacI. Finally 
pET26b (Novagen), which carries the pelB N-terminal signal peptide coding 
sequence, was digested with NcoI and SacI, and all three digested fragments 
ligated together to form pET26-StxBintC. To construct pET26-StxB, we used 
PCR with pET26-StxBintC as a template and primers T7 (5’-
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AATACGACTCACTATAGG) and StxB1-Sac (5-
GTTGAGCTCTTACCTAAAGATCACCTCAGAGAA). The PCR product and 
pET26b were digested with NcoI and Sac I and ligated to make pET26-StxB1. To 
make pET26-IntC, he IntC coding sequence was obtained from pNR50 (Judge, 
Mason et al. 2004) by digestion with NcoI and SacI, and ligated with pET26b that 
had been digested likewise. All plasmid constructs were sequenced to confirm the 
inserts.  
2.2. Bacterial expression and purification of StxB1, IntC and StxB1-IntC  
The plasmids pET26-IntC, pET26-StxB1, and pET26-StxB1IntC were mobilized 
into E. coli BL21 (DE3) by electroporation, and were confirmed in clones by 
plasmid preparation and restriction digestion. The bacteria were grown overnight 
at 37°C in Petri dishes containing solid medium Luria-Bertani (solid LB: 10 g/l 
bacto-tryptone, 5 g/l bacto-yeast, 10 g/l NaCl, 8 g/l agar, pH 7.0) supplemented 
with 50 mg/l kanamycin (LB-kan) as the selective agent. One bacterial colony 
was selected and grown overnight in 5 ml liquid LB-kan. The 5 ml bacterial 
culture used to inoculate 500 ml LB-kan. When the large bacterial culture reached 
0.6-0.8 optical density at 600 nm (OD600), 1mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) was added to the culture, which was grown for 5 h 
at 30°C with shaking. Cells were harvested by centrifugation at 5000xg for 30 
minutes (Avanti J-E, Beckman Coulter, Brea, CA), the supernatant removed and 
the cell pellet washed with 1X phosphate buffered saline (PBS, 137 mM NaCl, 
2.7 mM KCl, 10 mM sodium phosphate dibasic, 2 mM potassium phosphate 
monobasic, pH of 7.4), the pellet was weighed and saved overnight at -80°C. The 
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bacterial pellet was resuspended in 10 ml binding buffer (20mM sodium 
phosphate, 20mM imidazole, and 500mM sodium chloride) per gram of pellet. 
Bacterial cells were lysed by sonication (550 Sonic Dismebrator, Fisher 
Scientific, Pittsburg, PA) on ice until the cloudy solution became clear. The 
bacterial lysate was centrifuged for 30 min at 10,000xg and His-tagged protein 
was purified using a Ni Sepharose high performance HisTrap-HP column (GE 
Healthcare, Piscataway, NJ), according to the manufacturer’s instructions. 
Fractions eluted with 500mM imidazole were collected and dialyzed against PBS 
using slide-a-lyzer dialyzing cassettes (Pierce, Rockford, IL). 
 
2.3. SDS-PAGE and Western Blot  
The total soluble protein (TSP) content of each HisTrap-HP elution fraction was 
determined by BCA assay (Pierce, Rockford, IL), using BSA as the reference 
standard. For denaturing conditions, equal amounts of TSP were mixed with 6x 
SDS gel loading buffer (300mM Tris-HCl, pH 6.8, 600mM dithiothreitol, 12% 
SDS, 0.6% bromophenol blue, 60% glycerol). Samples were boiled for 15 min, 
placed on ice, and centrifuged 5 s before loading them on a pre-cast 4-20% Tris-
HCl sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) (BioRad, Hercules, 
CA). For non-denaturing conditions; proteins were not boiled or no DDT was 
added.  Proteins were separated by electrophoresis at 35mA for 2 h using Tris-
glycine running buffer (25mM Tris, 250mM glycine and 0.1% SDS) and a Bio-
Rad Mini-Protein apparatus (Bio-Rad, Hercules, CA). SDS-PAGE gels were 
stained with Coomassie dye (Fermentas, Glen Burnie, MD) or proteins were 
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transferred onto a polyvinylidene fluoride (PVDF) membrane at 80 volts for 2 h 
(Bio-Rad, Hercules, CA). The PVDF membrane was blocked overnight at 4˚C in 
5% dry milk in PBST (PBS buffer plus 0.1% Tween 20), and the next day the 
blocking continued for 2 h on a shaker at room temperature. The PVDF 
membrane was washed six times in PBST for 15 minutes each, and then incubated 
1 hour at 37˚C with rabbit polyclonal antibodies against Shiga toxin 1 (Wen, Teel 
et al. 2006b) or intimin protein diluted in 1% dry milk in PBST at 1:5000 and 
1:8000, respectively. The membrane was washed in PBST with agitation four 
times, 15 minutes each. The membrane was incubated with horseradish 
peroxidase-conjugated goat anti-rabbit IgG (Sigma-Aldrich, Saint Louis, MO) at 
1:10,000 dilution in 1% dry milk in PBST. ECL Plus kit (Amersham Biosciences, 
Piscataway, NJ) was used to detect bands specific for StxB (7.7 kDa), IntC (33 
kDa), or StxB-IntC fusion protein (40.7 kDa) as per the manufacturer’s 
instructions. Bacteria-derived purified IntC (expressed via pET26-IntC and 
purified in our laboratory) and StxB (BEI Resources, 
http://www.beiresources.org/) were used as positive controls. 
StxB1 and StxB1-intC purified samples were analyzed by Western blot in 
denaturing (1%SDS and 250mM DDT and boiled) and non-denaturing (no DTT 
added and not boiled) conditions. Pre-cast 4-20% Tris-HCl SDS-PAGE gels 
(BioRad, Hercules, CA) were used for western blot analysis.  
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2.4. Receptor binding of StxB1 and StxB1-IntC: Gb3 binding assay 
Globotriaosylceramide (Gb3) binding assay was modified based on Ashkenazi 
and Cleary (Ashkenazi and Cleary 1989). Gb3 (Matreya LLC, Pleasant Gap, PA) 
was dissolved in Chloroform/methanol (2:1) and 1µg Gb3 per well was added to 
high binding polystyrene EIA/RIA 96-well microplates (Corning, Glendale, AZ). 
Plates were incubated at 23˚C until all the fluid in the wells evaporated. Plates 
were washed with PBST three times and blocked with 5%BSA in PBST for 1 
hour at 37°C. After washing the plates three times with PBST, different amounts 
(25, 50, 100 and 150ng) of purified StxB1, StxB1-IntC, or IntC, proteins were 
diluted in 1% BSA/PBST and added to the plates. Plates were incubated for 1 
hour at 37°C, and washed three times with PBST, and incubated 1 hour at 37°C 
with rabbit polyclonal antibodies against StxB1 diluted in 1% dry milk in PBST at 
1:1000. After three washes with PBST plates were incubated with HRP-
conjugated goat anti-rabbit IgG (Sigma-Aldrich, Saint Louis, MO) at 1:10,000 
dilution in 1% dry milk in PBST. TMB peroxidase substrate (Bio-Rad, Hercules, 
CA) was used for detection, and the reaction was stopped with 1N H2SO4. The 
absorbance was read at 450 nm in an ELISA plate reader (MRX-tc, Dynex 
technologies, Chantilly, VA).   
 
2.5 Mouse Immunization and Challenge  
Twenty-four-week-old female BALB/c mice were separated into four different 
groups of seven animals each, and vaccinated with the StxB1, IntC and StxB1-
IntC proteins previously expressed and purified from E. coli. On day zero mice 
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were primed intraperitoneally (IP) with 0.5µg purified IntC, StxB1 , StxB1-IntC 
fusion protein or PBS. TiterMax Gold (Sigma-Aldrich, St. Louis, MO) was used 
as adjuvant according to the manufacturer’s instructions. On days 21, 28, and 42 
the mice were boosted intranasally (IN) with 30µg of either IntC, StxB1, or 
StxB1-IntC supplemented with 10µg of cholera toxin (CT, Sigma-Aldrich, Saint 
Louis, MO) as adjuvant.  
Blood samples were collected from the submandibular vein and incubated at room 
temperature for 10 minutes to let the blood coagulate. Samples were then 
centrifuged at 3000xg for 10 minutes, sera transferred to clean tubes, and saved at 
-20oC. Fecal pellets and vaginal lavages were collected from individually housed 
mice and saved at -20˚C. Proteins were extracted from fecal pellets using 1ml 
extraction buffer (10 µg/ml leupeptin, 0.1% Tween 20 in PBS) per 100 mg of 
fecal pellets. Samples were kept at 4°C for 20 minutes before a 1 min 
homogenization using a bullet blender homogenizer (Next Advance Inc., Averill 
Park, NY). Homogenized samples were centrifuged at 20,800xg in an Eppendorf 
Microcentrifuge 5417R (Eppendorf, Hauppauge, NY) for 10 minutes at 4°C. 
Cleared supernatant was collected and analyzed by ELISA immediately, or saved 
at -20°C for future tests. Vaginal lavages were thoroughly homogenized using a 
vortex, and samples were centrifuged in an Eppendorf Microcentrifuge 5417R at 
17900xg for 10 minutes at 4°C. 
For challenge studies, mice were challenged 14 days after the last boost. 
Previously immunized female BALB/c mice were fasted overnight and water was 
removed from the cages 4 hours prior to the bacterial administration. 
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Streptomycin resistant EHEC O157:H7 strain 86-24 Strr (Melton-Celsa, Rogers et 
al. 1998) were plated one night before on LB supplemented with streptomycin, 
and 2-3 colonies were selected from a fresh plate to prepare liquid culture.  
Bacteria were cultured in 25ml of LB culture containing 100µg/ml streptomycin 
and incubated on shaker at 37°C for 3 hours. The culture was centrifuged at 
3000xg and resuspended in freshly prepared, filter-sterilized 2.5 ml of 20% 
sucrose. Two doses were administered four hours apart and in each dose mice 
were fed (Mohawk, Melton-Celsa et al. 2010) 108-109 colony forming units 
(CFU) of bacteria. Following the challenge, fecal pellets were collected from 
individually caged mice to determine bacterial shedding. Fecal pellets were 
collected from individually caged mice and were diluted 1:10 by weight into PBS 
buffer. Then they are homogenized and centrifuged as described previously for 
ELISA and plated into sorbitol MacConkey agar supplemented with streptomycin.  
 
2.6. ELISA to determine IgG1 and IgG2a titers in mouse serum, and IgA titers in 
feces and vaginal lavages  
High binding polystyrene EIA/RIA 96-well microplate (Corning, Glendale, AZ) 
were coated with 50ng of either IntC or StxB1 proteins expressed in E. coli as 
described above. In order to compare antibody titers specific for StxB1 or IntC, 
plates were coated with StxB1 or IntC proteins, respectively, and incubated at 
room temperature for 4 h and then overnight at 4°C. Plates were washed with 
PBST (PBS pH 7.4 with 0.05% Tween 20) and blocked with 5% skim milk in 
PBST (5% PBST) for 1 h at 37˚C.  After another three washes with PBST, the 
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sera were two-fold serially diluted in the ELISA plate and incubated for 1 h at 
37˚C. After the plates were washed three times with PBST, they were incubated 
with  goat anti-mouse IgG1-HRP (Southern Biotech, Birmingham, Alabama) at 
dilution 1:2,500 in 1% skim milk in PBST (1% PBST) for IgG1 detection, or goat 
anti-mouse IgG2a-HRP (Southern Biotech, Birmingham, Alabama) at dilution 
1:2,500 in 1% skim milk in PBST for IgG2a detection. For IgA detection either in 
fecal pellets or in vaginal washes, goat anti-mouse IgA-HRP (Sigma-Aldrich, St 
Louis, Mo) was used at dilution 1:1,000 in 1% skim milk in PBST. Plates were 
washed 3 times with PBST and finally, detection was done using TMB peroxidase 
substrate (Bio-Rad, Hercules, CA). The reaction was stopped with 1N H2SO4 and 
absorbance read at 450 nm in an ELISA plate reader (MRX-tc, Dynex 
technologies, Chantilly, VA). Titers were calculated as the highest dilution factor 
of the serum that produced an absorbance reading of 0.1 at 450 nm after 
subtracting non-specific absorbance reading from non-treated mice.  
 
2.7. Statistical analysis  
The non-parametric Kruskal-Wallis test with Dunn’s Multiple Comparison post 
test was used to compare the levels of specific IgG1, IgG2a and IgA antibodies 
raised against StxB1 or IntC in immunized mice. A one-way ANOVA with a 
Bonferroni’s post test was used to compare the logarithms of CFU in feces from 
mice immunized with StxB1, IntC, or StxB1-IntC and then challenged with 
EHEC O157:H7.  All statistical analyses were performed using software Prism 5 
(GraphPad). 
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3. Results 
3.1. E. coli protein expression and purification  
The pET26b expression vectors used in this study are represented in Figure 1. 
Bacterial lysates from E. coli expressing StxB, IntC, or StxB-IntC were purified 
by metal affinity using HisTrap-HP columns. The purified proteins were 
separated by SDS-PAGE and stained with Coomassie blue or analyzed by 
Western blot. The expected specific protein bands of 33kDa for IntC  (Fig. 2A 
and B), ~7.7 kDa for StxB1 (Fig. 3A and 3B), or 41kDa for StxB-IntC (Fig 4A 
and 4B), were observed in both Western blot and Coomassie blue stained SDS-
PAGE gels. Based on examination of Coomassie and silver-stained gels, we 















Figure. 1: Plasmid constructs pET26-StxB1IntC, pET26-StxB1, and pET26-IntC 
used for recombinant protein expression in E. coli. Antigen genes were cloned in 
pET26b, which provides periplasmic targeting by use of the pelB signal peptide. 
L, (G4S)2 linker; pelB SP, pelB signal peptide; 6His, tag of 6 histidines for metal 
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Figure 2. Expression of IntC. His-tagged IntC were expressed in E. coli, purified 
by metal affinity, and separated by SDS-PAGE. Gels were stained with 
Coomassie blue (A) or transferred to a PVDF membrane and probed with anti-
intimin antibodies (B).  E1-E3: elution fractions from the metal affinity column; 
M, protein molecular marker (protein sizes are in kDa.); CE, crude cell extract; 
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Figure 3. Expression of StxB1. His-tagged StxB1 were expressed in E. coli, 
purified by metal affinity, and separated by SDS-PAGE. Gels were stained with 
Coomassie blue (A) or transferred to a PVDF membrane and probed with anti-
StxB1 antibodies (B).  E1-E6: elution fractions from the metal affinity column; 
M, protein molecular marker (protein sizes are in kDa.); CE, crude cell extract; 




  63 
 Figure 4. Expression of StxB1-IntC. His-tagged StxB1-IntC was expressed in E. 
coli, purified by metal affinity, and separated by SDS-PAGE. Gels were stained 
with Coomassie blue (A) or transferred to a PVDF membrane and probed with 
anti-intimin antibodies (B, D and F).  E1-E5: elution fractions from the metal 
affinity column; M, protein molecular marker (protein sizes are in kDa.); CE, 
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3.2. Oligomer formation and Gb3 receptor binding of StxB1 and StxB1-IntC 
Evidence of pentamer formation upon expression of StxB1 and StxB1-IntC was 
observed on Western blots (Fig 5A). Under denaturing conditions, the expected 
monomer sizes of 7.7kDa and 40.7 kDa were observed corresponding to StxB1 
and StxB-IntC respectively (Fig. 5A). With non-denaturing conditions, higher 
molecular weight bands were observed, which suggest pentameric assembly of 
the B subunits. Monomer size bands were also observed for both StxB1 and 
StxB1-IntC under non-denaturing conditions, and the relative intensities suggest 
that the efficiency of assembly was ~90% for StxB1 and ~75% for StxB1-IntC. 
Binding activity of pentameric StxB1 and StxB1-IntC to Gb3 was measured by 
ELISA (Fig. 5B). StxB1 showed higher binding affinity than StxB1-IntC on a 
protein mass basis, but accounting for the 5-fold larger size of the fusion protein, 









 Figure 5. StxB1 and StxB1-IntC oligomer formation and binding to Gb3 receptor. 
(A) Western blot to detect denatured and non-denatured StxB1 and StxB1-IntC. 
Denature: samples were boiled in SDS sample buffer containing 100mM DTT. 
Non-denature: samples were not boiled and sample buffer did not contained DTT. 
In the non-denaturing condition, higher molecular weight protein bands were 
observed in both StxB1 and StxB1-IntC, indicating oligomer formation. (B) Gb3 
ELISA showed binding of StxB1 and StxB1-IntC antigens to Gb3. StxB1-std, 
recombinant StxB1 (BEI Resources); IntC, negative control. 
  66 
  67 
3.3. Mouse Immunization  
Immunization of BALB/c mice (Table 1) with purified StxB1, IntC or StxB1-IntC 
provoked specific serum IgG1 and IgG2a antibodies against StxB1 and IntC 
proteins. In all the immunized animals, serum IgG1 titers were higher than serum 
IgG2a titers, which suggested a predominantly type 2 T-helper cell (Th2) 
response. of the Th2 response is associated particularly with  humoral antibody 
responses. The StxB1-IntC fusion generated significantly higher (P<0.01) IgG1 
and IgG2a titers than mice immunized with either StxB1 or IntC alone (Fig. 6 and 
Fig. 7). IgA titers were detected in fecal samples and vaginal lavages in all of the 
mice in groups 1, 2 and 3 (immunized animals), but not those in group 4 (negative 
control mice). Higher fecal and vaginal IgA titers were observed in mice that were 
immunized with the StxB1-IntC fusion than in those immunized with StxB1 or 
IntC alone (Fig. 8 and Fig. 9). IgA titers in vaginal lavages were higher (Fig 9) 
than in fecal samples (Fig 8), but the protease-rich gut environment probably 









Table 1. Mice immunization groups and treatments: Mice in group I were primed 
with IntC alone,  mice in group II were primed with StxB1 alone, mice in group 
III were primed with StxB1-IntC fusion protein. Prime was performed 
intraperitonally (I.P.) and TiterMax used as an adjuvant for all of the groups. Mice 
in were boosted intranasally with 30µg of same antigen that they were primed 
with.   
 
Groups Prime 1st Boost 2nd Boost 3rd Boost
Group I 0.5 µg B. IntC I.P. 30 µg T. IntC I.N. 4 µg T. Intimin I.N. 30 µg T. Intimin I.N.
(with TiterMax) (with 10 µg CT) (with 10 µg CT) (with 10 µg CT)
Group II 0.5 µg B.StxB1 I.P. 30 µg B. StxB1 I.N. 30 µg B. StxB1 I.N. 30 µg B. StxB1 I.N.
(with TiterMax) (with 10 µg CT) (with 10 µg CT) (with 10 µg CT)
Group III 0.5 µg B. StxB1-IntC I.P. 30 µg B. StxB1-IntC I.N. 30 µg B. StxB1-IntC I.N. 30 µg B. StxB1-IntC I.N.
(with TiterMax) (with 10 µg CT) (with 10 µg CT) (with 10 µg CT)
Group IV PBS I.P.
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 Figure 6. Serum IgG1 antibodies specific for intimin (A) or StxB1 (B) elicited in 
mice immunized with IntC, StxB1 or StxB1-IntC. Mice were primed IP with 
0.5µg of the indicated antigen, followed by IN boosting with 30µg of the same 
antigens at days 21, 28, and 42. Sera were obtained 14 days after the last boost. 
Mice immunized with StxB1-IntC raised significantly higher (P<0.01) antigen-
specific IgG1 antibody compared to mice immunized with IntC (A) or StxB1 (B). 
GMT, geometric mean titer (heavy bar) ± 95% CI (confidence interval). The 7 
individual mouse endpoint titers are shown as data points. 
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 Figure 7. Serum IgG2a antibodies specific for intimin (A) or StxB1 (B) elicited in 
mice immunized with IntC, StxB1 or StxB1-IntC. Mice were primed IP with 
0.5µg of the indicated antigen, followed by IN boosting with 30µg of the same 
antigens at days 21, 28, and 42. Sera were obtained 14 days after the last boost. 
StxB1-IntC immunized mice produced significantly higher (P<0.01) antigen-
specific IgG2a antibodies compared to IntC (A) or StxB (B). GMT, geometric 
mean titer (heavy bar), ± 95% CI (confidence interval). The 7 individual mouse 
endpoint titers are shown as data points. 
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Table 2. IgG1 to IgG2a ratios in immunized mice 
 
Mouse # Int-C StxB1-IntC StxB1 StxB1-IntC
1 8 4 0.25 2
2 16 2 0.125 2
3 16 2 0.25 2
4 2 4 1 4
5 16 4 0.25 4
6 2 8 0.5 8
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Figure 8. Fecal IgA specific for intimin (A) or StxB1 (B) in mice immunized with 
IntC, StxB1, or StxB1-IntC. StxB1-IntC immunized mice produced significantly 
higher (P<0.01) antigen-specific fecal IgA antibody compared to IntC (A) or StxB 
(B). GMT, geometric mean titer (heavy bar) ± 95% CI (confidence interval). The 
7 individual mouse endpoint titers are shown as data points. 
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Figure 9. Vaginal IgA specific for intimin (A) or StxB1 (B) in mice immunized 
with IntC, StxB1, or StxB1-IntC. Mice immunized with StxB-IntC raised 
significantly higher (P<0.01) antigen-specific vaginal IgA antibody compared to 
mice immunized with IntC (A) or StxB1 (B). GMT, geometric mean titer (heavy 
bar) and 95% CI (confidence interval). The 7 individual mouse endpoint titers are 
shown as data points.. 
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3.4. Challenge of Immunized Mice 
In this study, shedding of streptomycin-resistant E. coli O157:H7 strain 86-24 was 
evaluated for 11 days after challenge (Fig. 10). Mice in the control group shed the 
bacteria for the full evaluation period (11 days). Mice immunized with StxB1 
alone also shed the bacteria for 11 days, although at lower rates than the negative 
control mice for the first 5 days. Conversely, mice immunized with IntC or 
StxB1-IntC cleared the bacteria from their systems in six days and three days, 
respectively. Thus, we observed a benefit of immunization with the StxB1-IntC 
fusion protein over IntC alone. Mice immunized with StxB1-IntC cleared the 
bacteria significantly faster than those mice immunized with either IntC alone or 
StxB1 alone (P<0.001). We did not observe any weight change or abnormal 
behavior in mice after the challenge (data not shown).  
The time of bacterial shedding in mice immunized with StxB1-IntC fusion protein 
was significantly reduced compare to mice immunized with IntC (P<0.001), StxB 
(P<0.001), or no treated control (P<0.001) group (3, 6, 11, and 11 days, 








 Figure 10. Bacterial shedding after challenge with E. coli O157:H7 strain 86-24 
Strr. Mice immunized with StxB1, IntC or StxB1-IntC, or sham-immunized 
control mice were fed bacteria, and streptomycin resistant bacteria shed in feces 
were counted each day up to 11 days after challenge. The data points are means ± 
SD of 3 replicate determinations. The length of bacterial shedding in mice 
immunized with StxB1-IntC fusion protein was significantly reduced compare to 
mice immunized with IntC (P<0.001), StxB (P<0.001), or no treated control 
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4. Discussion 
HUS caused by EHEC infection is a medical emergency that results in 5-10% 
mortality. It is the most frequent cause of acute renal failure in children, although 
the majority of the infected people recover completely (Corrigan and Boineau 
2001). The most common route of EHEC infection is food-borne, which explains 
up to 85% of the cases. Meat products cause most infections, but vegetables such 
as spinach can also be sources (Maki 2006; Grant, Wendelboe et al. 2008). 
Despite the high incidence of severe EHEC infections, there is no available 
commercial vaccine to prevent this disease. Moreover, antibiotic therapy is not 
considered to be an effective method to treat the infection, since antibiotics might 
cause the release of more bacterial toxin, which increases the risk of HUS (Wong, 
Jelacic et al. 2000; Amirlak and Amirlak 2006; Iijima, Kamioka et al. 2008; 
Bavaro 2009). .  
Since Donnenbergi et al. (Donnenberg, Tzipori et al. 1993) reported the 
requirement of intimin for attachment of the E. coli O157:H7 to the host cell, 
intimin has been proposed as a vaccine candidate to prevent E. coli O157:H7 
colonization. Gansheroff et al. (Gansheroff, Wachtel et al. 1999) demonstrated 
that the antibodies raised against intimin reduce colonization of E. coli O157:H7 
in mice, rabbit and Hep-2 cells in vitro.  Dean-Nystrom et al. (Dean-Nystrom, 
Gansheroff et al. 2002) showed that intimin administered to pregnant swine 
protects them from developing intestinal lesions, and furthermore, their colostrum 
protects the suckling piglets from colonization by E. coli O157:H7.  Judge et al 
(Judge, Mason et al. 2004) tested a plant cell-based intimin vaccine in mice and 
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reported a significant decrease in the duration of colonization by E. coli O157:H7 
in treated mice as compared to the control group (8.6 days versus 13.4 days, 
respectively). They primed mice IP with 15µg of plant-derived intimin and then 
boosted them orally (feeding) with 15µg of plant-derived intimin. Agin et al. 
(Agin, Zhu et al. 2005) used an intimin mutant E. coli strain to prevent 
colonization of E. coli O157:H7 in rabbits. The intimin-specific antibodies raised 
by these animals conferred protection against E. coli O157:H7 infections. Cataldi 
et al (Cataldi, Yevsa et al. 2008)  reported a systemic and mucosal immunity in  
mice after intranasal immunization with 20µg of bacterially derived intimin. 
McNeilly et al (McNeilly, Mitchell et al., 2010) immunized cattle with a mixture 
of purified intimin, EspA (E. coli secreted protein A) and Tir, which reduced the 
shedding of E. coli O157:H7. Based on these reports that support the intimin 
protein as a vaccine candidate, we developed a transgenic tomato plants 
expressing IntC (Chapter 2).  Unfortunately, many recombinant antigens are 
poorly immunogenic when they are administered only by the mucosal route 
(Cataldi, Yevsa et al. 2008). Moreover, our IntC delivered IN required a priming 
dose delivered parenterally in order to maximize its efficacy. Therefore, there is a 
great need for strategies to improve the mucosal immunogenicity of recombinant 
vaccines.   
In the present study, we used a fusion of the mucosal targeting molecule StxB1 to 
IntC as a strategy to induce strong mucosal and systemic antibody responses, with 
the idea that StxB1-IntC could be a more effective vaccine candidate than IntC or 
StxB1 alone. We demonstrated that StxB1-IntC induced stronger mucosal and 
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systemic immune responses, and conferred a more effective protection in the 
mouse model than IntC or StxB1 alone.  
Although StxB1 monomers contain Gb3 binding sites (Ling, Boodhoo et al. 
1998), the pentameric structure of StxB1 is likely to provide cooperative binding 
effects that enhance the binding of Gb3. Therefore, we confirmed the formation of 
B subunit oligomers Western blotting with proteins resolved under non-
denaturing conditions, and demonstrated efficient Gb3 binding of StxB1 and 
StxB1-IntC (Figs. 5A and 5B). Interestingly, the N-terminal 6-His tag on StxB1 
did not interfere with pentamer assembly, as >90% of the purified StxB1 showed 
assembled oligomers upon non-denaturing Western blot. The His-tagged StxB1-
IntC fusion protein assembled with less efficiency, but still the great majority of 
purified antigen displayed the oligomeric form. Moreover, the fusion protein 
bound Gb3 on a protein mass basis approximately equivalent to StxB1.  
Mice immunized with StxB-IntC produced higher titers of antigen-specific 
vaginal and intestinal IgA than those mice vaccinated with IntC or StxB alone. 
Vaginal antigen-specific IgA titers were approximately two times higher than the 
intestinal antigen-specific IgA titers. A possible explanation is that the route of 
antigen delivery plays an important role in generating site-specific antibodies 
(Holmgren and Czerkinsky 2005). In this study, even though the intranasal 
delivery of the antigen induced higher titers of vaginal IgA than intestinal IgA, the 
intestinal colonization time of the bacteria was reduced in mice vaccinated with 
IntC and StxB1-IntC compared to the control or StxB1 alone. Antigen-specific 
IgG1 titers were higher than the IgG2a titers in all the treatment groups, 
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suggesting a Th2 response, which is necessary to generate strong and protective 
IgA and IgG1 responses. We also found that mice immunized with StxB1-IntC 
generated a significantly higher (P< 0.01) IgG1 and IgG2a responses than those 
vaccinated with IntC or StxB1 alone.  
The time of bacterial shedding in mice immunized with StxB1-IntC fusion protein 
was significantly reduced compare to mice immunized with IntC (P<0.001), StxB 
(P<0.001), or no treated control (P<0.001) group (3, 6, 11, and 11 days, 
respectively) (Fig. 10). These results indicate that the StxB1-IntC fusion protein is 
a better candidate vaccine to limit E. coli O157:H7 intestinal colonization in mice 
than IntC alone.  
Mice immunized with StxB1 alone had a significant difference from control mice 
from days one through seven. These findings support a potential cross-reactivity 
between Stx1 and Stx2, because the challenge strain that we used produces Stx2. 
Some researchers (Donohue-Rolfe, Acheson et al. 1989; Bielaszewska, Clarke et 
al. 1997; Ludwig, Karmali et al. 2002) observed immunological cross-reactivity 
between Stx1 and Stx2. However, Wen et al. (2006a) and Strockbine et al. (1988) 
reported no cross-neutralizing activity between Stx1 and Stx2. In our study, mice 
immunized with StxB1 showed significantly less bacterial shedding during days 
one through seven, but the difference disappears starting at day eight and 
thereafter shows the same pattern as unimmunized mice. Mohawk et al. 
(Mohawk, Melton-Celsa et al. 2010) showed that neutralizing antibodies against 
Stx2 reduce the colonization by Stx2 producing bacteria, and thus our observation 
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of a slight protective effect by immunizing with StxB1 is consistent with a slight 
cross-reactivity with StxB2.  
However, we must also consider that StxB was shown to have an adjuvant 
activity. These workers (Ohmura-Hoshino, Yamamoto et al. 2004) found that 
StxB administered IN with ovalbumin induced the up-regulation of CD80, CD86, 
and CD40 on dendritic cells of the nasal associated lymphoid tissue, and produced 
stronger antibody responses than ovalbumin alone. Thus, they suggest that StxB 
could be used as a mucosal adjuvant for the induction of Th2-type, CD4+ T cell 
mediated mucosal IgA and systemic IgG responses.  Therefore, the presence of 
StxB1 in our fusion protein might be acting to enhance the presentation of IntC 
antigens by nasal dendritic cells, thus boosting antibody responses.  
An alternative explanation is that the binding of StxB1 to its Gb3 receptor drove 
more efficient mucosal (IN) delivery of IntC and thus provoked stronger antibody 
responses in mice vaccinated with the StxB1-IntC fusion than in mice that 
received StxB or IntC alone. Another study (Haicheur, Benchetrit et al. 2003) 
showed enhanced IgG2a antibody responses in mice immunized with ovalbumin 
chemically coupled to StxB, as compared to ovalbumin alone. They found that 
that the StxB component induced antigen-specific CTL and humoral antibody 
responses with a Th1-type polarization. We also observed a higher anti-IntC 
IgG1/IgG2a ratio induced by immunization with the StxB1-IntC fusion as 
compared with IntC alone, but IgG1 was still dominant. Thus, we obtained a 
mixed Th1/Th2 type response to IntC, which could have been mediated by the 
StxB1 component. The higher antibody titers might facilitate a faster clearing of 
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the ingested bacteria from the gut. Another feasible explanation for enhanced 
immunogenicity of the fusion protein is the interaction of intimin with the 
nucleolin receptor (Sinclair and O'Brien 2004), although this binding is not as 
specific as StxB1 to its Gb3 receptor.  
Based on our results with StxB1-IntC, it is likely that fusion proteins with StxB1 
can be used for other vaccine candidates, especially those that could benefit form 
mucosal immune responses. Taken together, the results presented here 
demonstrate for the first time the potential of StxB1-IntC fusion protein as a 
multi-component vaccine candidate to limit E. coli O157 H7 infections, and show 


















ELECTRON MICROSCOPY  
Abstract 
E. coli O157:H7 protein, intimin, is an important vaccine candidate since it has 
been proven to reduce colonization of the host by these bacteria (Ghaem-
Maghami, Simmons et al. 2001; Dean-Nystrom, Gansheroff et al. 2002; Judge, 
Mason et al. 2004; Agin, Zhu et al. 2005; Carvalho, Teel et al. 2005; Cataldi, 
Yevsa et al. 2008). As previously described, we expressed C terminal of intimin 
in tomato plants and we used two different constructs, pNR49 and pNR50 (see 
chapter 2). Selected transgenic lines were grown in the tissue culture first and they 
were transferred to the green house for maturation.  
In this chapter we investigate the differences and similarities at the sub-cellular 
level between the plants that were transformed with pNR49 and plants 
transformed with pNR50.   
 
1. Introduction 
In 1992 Mason et al (Mason, Lam et al. 1992) reported for the first time 
expression of hepatitis B surface antigen in transgenic tobacco plants. Ever since 
then, expression of different proteins to use as a vaccine candidate in plants has 
been an area of interest for over two decades (Thanavala, Huang et al. 2006). 
Demand for recombinant biopharmaceutical has been growing recently and plants 
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are one of the popular approaches to fulfill this demand since plants are 
inexpensive for large scale production and free from human pathogens (Mett, 
Farrance et al. 2008; Tiwari, Verma et al. 2009).  
We also have used tomato plants to express intimin as a vaccine candidate to 
prevent colonization of the host by E. coli O157:H7. 
 
2. Materials and method 
Lycopersicon esculentum variety Tanksley TA234 plants were grown in the green 
house. Green fruit excised from the elite lines and surface sterilized with 70% 
ethanol and they were thoroughly washed with sterile water. Green fruit pericarp 
samples cut into approximately 2X2 mm in the primary fixative, which contains 
2% glutaraldehyde and 2% paraformaldehyde in 50mM sodium phosphate buffer. 
Samples were then fixed in the same fixative for 2 hours at 4˚C. Plant samples 
were washed in 50mM sodium phosphate buffer for 30 minutes. All of the 
samples were then post fixed in 2% osmium tetroxide at 23˚C for 2 hours. Tissue 
samples were washed in 50mM sodium phosphate buffer, followed by 
dehydration in graduated ethanol series (10, 20, 30, 40, 60, 80 and 100% ethanol) 
at room temperature. Lastly tissue samples were infiltrated with spur and molded 
at 60˚C.  Embedded tissue samples were cut into thin section by using Leica 
Ultracut R microtome and sections were observed on transmission electron 
microscope (Philips CM12S Scanning Transmission EM).  
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3. Results and Discussion 
Physiologically, tomato fruit from the plants transformed with pNR50 were 
smaller than fruit from those that were transformed with pNR49. The plants 
transformed with pNR50 had less foliage compared to either plants transformed 
with pNR49 or the non-transformed tomato plants (wild type). Plants transformed 
with pNR49 had more intimin expression level (Chapter 2).  
We observed cellular structure of the plants that were transformed either with 
pNR49 or pNR50 and wild type (non-transformant) by electron microcopy. We 
used leaves (Fig. 1) and the fruit of the line 49-4b.3 (Fig. 2), leaves (Fig.3) and 
fruit (Fig. 4) of 50-7.3 and used wild type tomato leaves (Fig. 5) and fruit (Fig6). 
We observed endoplasmic reticulum (er) or rough endoplasmic reticulum (rer), 
chloroplast (ch), cell wall (cw), golgi (g) or trans golgi network (tng) 
mitochondria (m), nucleus (n), nuclear envelope (ne) and plasmodesmata (pd). 
Among all of the samples we did not observe any difference in subcellular 
structured between the leaves and fruits that were transformed with either pNR49 
or pNR50. Although we have observed some physical differences between two 
different transgenic lines (49-4b.3 and 50-7.3) we did not observe any differences 









Figure 1. Transmission electron microscopy of the leaf of T1 elite line: 49-4b.3. 




  85 
  
 
Figure 2. Transmission electron microscopy of fruit of T1 elite line: 49-4b.3. ch: 
chloroplast, er: endoplasmic reticulum, cw: cell wall, g: golgi, tgn: trans golgi 
network, m: mitochondria, ne: nuclear envelope.  
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Figure 3. Transmission electron microscopy of the leaf of T1 elite line: 50-7.3 
leaf. ch: chloroplast, cw: cell wall, g: golgi, m: mitochondria, n: nucleus, nu: 
nucleolus, pd: plasmodesmata.  
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Figure 4. Transmission electron microscopy of the fruit of T1 elite line: 50-7.3 
fruit. ch: chloroplast, m: mitochondria, n: nucleus, nu: nucleolus.  
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Figure 5. Transmission electron microscopy of wild type tomato leaves. ch: 
chloroplast, m: mitochondria, ml: middle lamella, n: nucleus, ne: nuclear 
envelope.  
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Figure 6. Transmission electron microscopy of wild type tomato fruit.  m: 
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CONCLUSIONS 
This dissertation has focused the development of a vaccine to prevent E. coli 
O157:H7 attachment and colonization. The bacterial outer membrane protein 
intimin was used as a vaccine candidate, because intimin has a primary role in the 
intimate attachment of the E. coli O157:H7 to the host cell. The first step was the 
expression of intimin protein using plants as an expression system. The C-
terminal 281 amino acids (~1/3) of the intimin protein (IntC) was expressed in 
tomato and the transgenic plants were tested by ELISA and Western blotting to 
confirm expression of antigen. Freeze-dried fruit samples that were kept at room 
temperature for a year showed no degradation. Therefore, this inexpensive and 
well-established freeze-drying technology was used to preserve the recombinant 
IntC from protein degradation. Plant-derived IntC was purified from the 
transgenic freeze-dried tomato powder. Since IntC glycosylation was reported in 
plant cells, we tested tomato-derived IntC for glycosylation. We observed no 
evidence of glycosylation in the tomato-derived IntC. The immunogenicity of 
IntC was tested in mice. After mice were immunized with plant-derived IntC, 
antigen-specific antibody  responses were induced in the vaccinated animals. In 
addition, the duration of  the bacterial shedding after the challenge with E. coli 
O157:H7 was significantly reduced in mice vaccinated with the plant-derived 
IntC vaccine.  
Shiga toxin is produced by E. coli O157:H7 and it is the main cause of the HUS in 
humans. It is composed of an A subunit and a pentameric B subunit. The B 
subunit (StxB) is responsible for the binding of the toxin to its receptor, Gb3. We 
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designed, constructed, and expressed a fusion protein consisting of StxB and IntC 
(StxB1-IntC) in E. coli. IntC and StxB were separately expressed in E. coli as 
well. All recombinant proteins were purified and tested by Western blotting and 
Coomassie blue staining before their use in animal trials. The oligomeric 
formation of StxB was confirmed by non-denaturing SDS-PAGE, and its Gb3 
binding was demonstrated. Since StxB can act as an adjuvant, the purified StxB1-
IntC was expected to raise a better immune response than mice immunized with 
IntC or StxB1 alone. In fact, mice immunized with the StxB1-IntC fusion protein 
produced better serum and mucosal antibody responses than mice immunized 
with IntC or StxB1 alone. In addition, mice that were immunized with the StxB1-
IntC fusion protein and then challenged with E. coli O157:H7 shed the bacteria 
for shorter periods than those immunized with IntC or StxB1 alone.  
This study is a very important step towards developing a vaccine to prevent E. 
coli O157:H7 colonization of cattle and indirectly prevention of the infection in 
humans. The mucosal immune response is important for protection against 
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